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CHAPTER 1 INTRODUCTION
Parts of this chapter have been published in Yu, W., and Greenberg, M. L. (2016)
Inositol depletion, GSK3 inhibition and bipolar disorder. Future Neurology. (In press)
Bipolar disorder (BD) is a severe psychiatric illness affecting about 2% of the
world population. BD patients suffer from recurring cycles of mania and depression,
which greatly hamper interpersonal relationships and career success. The mortality rate
of BD patients is 15-20% higher than that of the general population (1). Approximately
15% of BD patients commit suicide (2). Lithium and valproic acid (VPA) are among the
most widely used and best-studied mood stabilizers (3,4). However, these and other
major anti-bipolar therapies cause serious side-effects and have limited efficacy (5).
Thus, there is a great demand for more effective anti-bipolar drugs. Efforts to develop
new treatments for BD are hampered by the lack of knowledge of the therapeutic
mechanisms of the current drugs. Several hypotheses have been proposed to elucidate
the mechanisms underlying the mood-stabilizing effects of the drugs. In this review, we
focus on the controversies and connections characterizing two current hypotheses of
the therapeutic mechanisms of lithium and VPA – inositol depletion and GSK3 inhibition
– and suggest that the two mechanisms may be related.
1. Inositol depletion hypothesis
1.1. Inositol metabolism
Myo-inositol is the precursor of all inositol lipids and inositol phosphates.
Eukaryotic cells obtain inositol by three routes. Inositol is taken up from the surrounding
environment by inositol transporters (6,7). In the absence of exogenous inositol, it is
synthesized de novo from glucose-6-phosphate (G6P) in a two-step reaction (Fig. 1-1).
G6P is first converted to inositol-3-phosphate by myo-inositol-3-phosphate synthase
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(MIPS), which is encoded by ISYNA1 and INO1 in human and yeast cells, respectively
(8-11). The second step is the conversion of inositol-3-phosphate to inositol, which is
catalyzed by inositol monophosphatase (IMPase) (12). Inositol is also obtained by
recycling inositol phosphates (13). The levels of inositol in brain are significantly higher
than in blood and other tissues (14), suggesting that high levels of inositol are critical for
normal brain function. Although brain cells can take up inositol from the blood, uptake is
slowed by the blood-brain barrier (15,16), suggesting that inositol de novo synthesis and
the recycling of inositol phosphates are the main sources of inositol in brain (17).
Inositol is an essential substrate for the synthesis of phosphatidylinositol (PI),
from which are derived the phosphatidylinositol phosphates. Seven known
phosphatidylinositol phosphates are derived from PI, including PI(3)P, PI(4)P, PI(5)P,
PI(3,4)P2, PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P3 (18). Phosphoinositides are signaling
molecules that mediate cell growth, proliferation, apoptosis, insulin action and many
other cellular events (19). It is not surprising, therefore, that perturbation of
phosphoinositide metabolism is associated with many disorders (18). Upon receptor
mediated activation of phospholipase C (PLC), PI(4,5)P 2 is cleaved to form inositol1,4,5-triphosphates (IP3) and 1,2-diacylglycerol (DAG) (20). IP3 can be recycled to myoinositol by a series of dephosphorylations catalyzed by inositol polyphosphate
phosphatase and IMPase (21). Alternatively, IP3 can be phosphorylated sequentially to
form IP4, IP5, and IP6 by inositol phosphate kinases (13,21). These molecules convey
signals for a variety of cellular processes, although the functions of inositol phosphates
are not fully understood (22,23). Inositol phosphates can be further phosphorylated on
existing phosphate groups to form pyrophosphates (24,25), whose functions are
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Figure 1-1. The inositol de novo synthesis pathway. Inositol is synthesized in a twostep reaction. Glucose 6-phosphate (G-6-P) is converted to inositol-3-phosphate (I-3-P)
by myo-inositol-3-phosphate synthase (MIPS), which is the rate-limiting enzyme of
inositol synthesis. At the second step, I-3-P is dephosphorylated by inositol
monophosphatase (IMPase) to generate myo-inositol.

4

involved in the regulation of gene expression, vesicular tracking and DNA repair (26-28).
Many inositol-containing molecules function as metabolic sensors that regulate
neuronal function and neurotransmission (13). For example, IP3 is a second messenger
that activates the release of calcium from cellular storage (20). Calcium signaling
regulates neuronal differentiation, apoptosis, and exocytosis (29). Many receptors in the
central nervous system activate PLC-dependent cleavage of PIP2 and increase
IP3/calcium release (30). Perturbation of intracellular inositol metabolism has been
associated with bipolar disorder, Alzheimer’s disease, diabetes and cancer (18).
Therefore, maintaining stable inositol homeostasis is critical for normal cellular function
(13,31).
1.2. Altered inositol levels in BD
A correlation has been observed between BD and altered levels of inositol in
brain. Altered myo-inositol and phosphoinositide levels have been observed in brains of
living BD patients using magnetic resonance spectroscopy (32-34). Higher myo-inositol
signals were detected in brains of BD patients during the manic phase (35). Conversely,
significantly lower levels of myo-inositol were identified in the frontal cortex of BD
patients during the depressive phase (36). Frontal cortex samples from postmortem BD
patients also exhibited decreased myo-inositol levels (37). Furthermore, myo-inositol
levels were reduced in cerebrospinal fluid obtained from affective depression patients
(38). Interestingly, dietary supplementation of inositol (12g/day for 4 weeks in one study)
led to significant efficacy for the treatment of depression (39,40). Inositol also alleviated
depression in animal models (41,42). These studies suggest that abnormal brain inositol
levels may play a role in mood disorders.
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1.3. VPA and lithium inhibit inositol synthesis
Despite the fact that lithium has been used for more than 60 years for the
treatment of BD, the therapeutic mechanism of the drug remains unknown (4). Similarly,
the mechanism underlying VPA efficacy is not understood (43). Lithium was shown to
be an uncompetitive inhibitor of IMPase, which catalyzes the conversion of inositol-3phosphate to myo-inositol (44-46). Berridge and co-workers hypothesized that inhibition
of inositol synthesis by lithium leads to decreased PI synthesis and subsequent
attenuation of PI signaling (46). These pivotal studies laid the foundation for the inositol
depletion hypothesis as a potential therapeutic mechanism of action of lithium. In
support of the hypothesis, studies in animal models suggested that the mood-stabilizing
effect of lithium is correlated with inhibition of inositol synthesis. Lithium reduced myoinositol levels in rat brain (47). Inositol levels in rat cerebral cortex decreased 30% by 6
h after lithium injection, and the reduction of inositol persisted for 24 h. In addition, VPA
and lithium treatment led to a reduced intracellular concentration of IP3 (17,48,49).
Lithium-induced inositol depletion resulted in reduction of PIP 3 (49,50). Inositol deficient
diet augmented the effect of lithium in behavioral studies (51). These studies support
the hypothesis that mood-stabilizing drugs suppress PI signaling via affecting inositol
metabolism. Inositol depletion also affects other cellular functions that are associated
with psychiatric illness. Inositol depletion and VPA treatment altered PI(3,5)P 2
homeostasis and perturbed vacuolar ATPase function in yeast; while similar studies
have not yet been carried out in mammalian cells, these functions are important for
neurotransmission (52). VPA and lithium prompted synapse formation between
hippocampal neurons, which could be reversed by pretreatment with exogenous inositol
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(53). Inositol depletion resulted in defective craniofacial development and brain function
in a mouse model (54).
Understanding how inositol synthesis is regulated is of obvious importance to
elucidating drug-related mechanisms of inositol depletion. Surprisingly, regulation of
inositol synthesis in mammalian cells has not been well-studied. In contrast, inositol
synthesis has been well characterized in the yeast Saccharomyces cerevisiae (55-57).
In this yeast, both lithium and VPA were shown to inhibit inositol synthesis. Lithium
reduces intracellular inositol levels in yeast, as in human cells, by inhibiting inositol
monophosphatase (58,59).

Interestingly, VPA was also shown to perturb inositol

metabolism in yeast (59). VPA depletes inositol by a different mechanism from that of
lithium. Vaden et al. first discovered that VPA causes decreased levels of intracellular
inositol-3-phosphate and inositol in yeast (59), consistent with inhibition of MIPS, which
catalyzes the synthesis of inositol-3-phosphate from G6P. Indeed, VPA was shown to
cause a 35% decrease of MIPS enzymatic activity in vivo at a drug concentration used
therapeutically (0.6 mM). Subsequent studies showed that VPA also inhibited human
MIPS expressed in yeast cells (60). In contrast to direct inhibition of IMPase by lithium,
inhibition of MIPS activity is indirect and not observed in vitro. Indirect inhibition of MIPS
by VPA is also observed in human brain (61). Consistent with inositol starvation, chronic
VPA treatment significantly decreased PI synthesis and increased CDP-DAG levels in
yeast (62).
Both yeast and human MIPS are phosphoproteins, and phosphorylation of MIPS
has been shown to regulate activity of both enzymes (63,64). Three phosphorylation
sites were identified and mapped to Ser-184, Ser-296 and Ser-374 in yeast MIPS and
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the corresponding sites Ser-177, Ser-279, and Ser-357 in human MIPS. VPA was
shown to increase phosphorylation of yeast MIPS (64). The simultaneous mutation of
both Ser-184 and Ser-374 to Ala resulted in a four-fold increase in MIPS enzyme
activity and decreased sensitivity of cells to VPA (64). Although inhibition of MIPS by
VPA is indirect, VPA directly or indirectly affects protein kinase A (PKA), AKT (also
known as protein kinase B), glycogen synthase kinase-3 (GSK3), and protein kinase C
(PKC) signaling pathways (65-67). Therefore, it is plausible that inhibition of MIPS by
VPA may be an indirect outcome of affecting these kinases.
VPA-mediated perturbation of inositol metabolism was also reported in animal
studies. VPA and lithium caused similar levels of inositol depletion in rat brain (68).
Acute VPA treatment reduced inositol levels in mouse frontal cortex tissue (61). Inositol
reversed the inhibitory effects of VPA and lithium on the collapse of sensory neuron
growth cones and the increase in growth cone area in rat ganglia cells (17). These
studies indicate that inositol depletion is a common outcome of structurally disparate
anti-bipolar drugs.
1.4. Inositol depletion and PKC
PKC, a target of lithium and VPA that is associated with BD, is affected by
inositol. PKC comprises a family of serine/threonine kinases that are ubiquitous in
mammalian tissues (69). It is highly enriched in brain, where its activity affects
numerous cellular processes, including neurotransmission, secretion, cell proliferation
and localization of extracellular receptors (70). Several PKC isoforms are activated by
DAG, the signaling molecule generated from the cleavage of PIP 2 (71). Numerous
studies associate PKC with the pathophysiology and treatment of BD. Serotonin-
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induced PKC translocation was altered in platelets obtained from BD patients during the
manic phase (72). The ratio of membrane-bound to cytosolic PKC activities was shown
to be elevated in BD patients and decreased after lithium treatment (72). Alteration of
PKC levels and activities were also reported in a study of postmortem BD brain (73).
Furthermore, a genome-wide association study identified diacylglycerol kinase η (DGKH)
as a risk gene in the etiology of BD (74). DGKH catalyzes the metabolism of DAG to
phosphatidic acid. Because DAG is a necessary cofactor for many isoforms of PKC,
DGKH is thought to attenuate PKC (75). A study of post-mortem brain tissue
demonstrated increased expression of DGKH in the prefrontal cortex of BD patients (76),
suggesting that altered expression of DGKH is involved in the pathogenesis of BD.
Taken together, these findings suggest a close association between perturbation of the
PKC pathway and BD.
Interestingly, both lithium and VPA were shown to reduce PKC levels (77). Rats
chronically treated with lithium exhibited a decrease in membrane-associated PKC α in
hippocampus (78). The co-administration of myo-inositol reversed the decrease in PKC
α and ε levels in hippocampus samples of rats treated with lithium (79). Chronic
treatment with VPA also reduced levels of PKC α and ε in rat cells (80). Tamoxifen, a
strong inhibitor of PKC widely used for the treatment of breast cancer, exhibited
significant efficacy in reducing manic symptoms, although it was not effective for BD
patients during the depression phase (81).
In summary, perturbation of PKC activity is closely associated with the etiology of
BD. It is tempting to speculate that down-regulation of PKC by lithium and VPA induces
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inositol depletion, which may exert therapeutic effects by altering downstream signaling
pathways.
1.5. Discrepancies of the inositol depletion hypothesis
Some studies do not support the inositol depletion hypothesis. First, reduction of
mouse brain inositol levels alone did not lead to mood stabilization (82). Mice
heterozygous for the null allele of the myo-inositol transporter 1 (SMIT1) gene exhibited
a 33-37% decrease in inositol in brain tissue, which was greater than the 22-25%
decrease observed in lithium treated mouse brain. However, only lithium treated mice,
but not SMIT+/- mice, exhibited a significant decrease in immobility in the forced swim
test (82,83). A second argument against the inositol depletion hypothesis is that inositol
depletion does not necessarily lead to decreased PI signaling. Phosphatidylinositol
levels were compared in WT and SMIT -/- mouse fetal brain. Although SMIT -/- mice
exhibited a 92% decrease in intracellular inositol, phosphatidylinositol levels were not
significantly changed (84). However, it is possible that 8% of WT levels of inositol
remaining in SMIT -/- mice may be sufficient to accommodate normal PI signaling. Third,
it is not clear how inositol depletion can effectively treat both mania and depression.
Studies by Cheng et al. suggested a mechanism whereby VPA and other mood
stabilizing drugs may exert their dual action by maintaining stable PI signaling (85).
Inositol depletion may attenuate PI signaling in manic patients, while VPA-induced
inhibition of prolyl oligopeptidase may increase PI signaling in depressed patients (85).
In summary, while many common outcomes of anti-bipolar drugs are well
explained by inositol depletion, some studies are not consistent with the hypothesis.
2. GSK3 inhibition hypothesis
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2.1. GSK3 activation is inhibited by lithium
In 1996, Klein and Melton reported that lithium is an inhibitor of GSK3β in
Xenopus (86). Subsequent studies showed that lithium inhibited GSK3β in Drosophila,
cultured mammalian cells, and rat brain (87-93). Lithium can directly inhibit GSK3 by
competing with the co-factor magnesium for binding to the enzyme (94), and/or by
prompting inhibitory serine phosphorylation through multiple mechanisms, including
PKA, phosphatidylinositol-3 kinase (PI3K)/AKT, PKC pathways, and autoregulation of
GSK3 (95-98). These findings led to the hypothesis that GSK3 inhibition may be the
therapeutic mechanism of mood-stabilizing drugs.
Glycogen synthase kinase-3 (GSK3) was first identified as a protein kinase that
phosphorylates and inactivates glycogen synthase (99,100). As a serine/threonine
kinase, GSK3 is involved in the regulation of many cellular functions that affect cell fate
determination, cell survival, and signal transduction (101-103). Two isoforms of GSK3
exist in mammalian cells, GSK3α and GSK3β (104,105). These isoforms exhibit 98%
identity in the amino acid sequences of their kinase domains (105). GSK3 activity is
regulated by the PI3K/AKT pathway, which phosphorylates GSK3α and GSK3β on
serine-21 and serine-9, respectively, inhibiting their enzymatic activities (106,107).
GSK3β, the predominant form in brain, regulates more than 40 proteins in many cell
signaling pathways, some of which play a role in BD as well as Alzheimer’s disease and
cancer (102,103,108,109).
To determine if GSK3β inhibition may account for the therapeutic effect of moodstabilizing drugs, behavioral efficacies of reduction of intracellular GSK3β and lithium
treatment were compared (110). Mice chronically treated with lithium exhibited
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significantly decreased immobility in the forced swim test, a positive anti-depressive
effect (111). Interestingly, mice with heterozygous deletion of GSK3β, in which GSK3β
levels are significantly decreased, also exhibited decreased immobility time in the forced
swim test, as well as other behavior changes similar to those seen in lithium treated
mice (110). Behavior changes observed in lithium treated and GSK3β +/- mice were
reversed by overexpression of GSK3β, indicating that GSK3β is a target of lithium (112).
Consistent with inhibition of GSK3 as a therapeutic mechanism, mood-stabilizing effects
were reported for many GSK3 inhibitors. Rodents treated with GSK3 inhibitors ARA014418 and L803–mts exhibited reduced immobility time in the forced swim test (113115). In addition to the anti-depressive effect, GSK3 inhibitors also reduced manic
behaviors in animal studies. A variety of GSK3 inhibitors reduced hyperactivity in mouse
models of mania (114,116). In addition, mice with heterozygous deletion of GSK3β also
exhibited attenuated amphetamine-induced hyperactivity (116). These findings suggest
that reduced GSK3 activity contributes to alleviation of manic behavior in animal models.
2.2. Inhibition of GSK3 by VPA
VPA was shown to inhibit GSK3β in some (117-120) but not all studies (121).
Chen and co-workers demonstrated that VPA inhibits GSK3 in both in vivo and in vitro
assays (117). The activities of GSK3α and GSK3β, assayed in vitro by incorporation of
32

P into cAMP response element-binding protein (CREB) phosphopeptides, decreased

in the presence of VPA in a concentration dependent manner. In vivo assays using βcatenin degradation as an indicator of GSK3β activity showed significant increases in βcatenin levels in cytosol and nucleus of VPA-treated neuronal cells, consistent with
GSK3 inhibition (117). Phosphorylation of tau protein by human GSK3β was also
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decreased in the presence of VPA in a concentration dependent manner (119).
Furthermore, VPA treatment inhibited phosphorylation of microtubule-associated protein
1B (Map-1B) by GSK3β in vivo in neuronal cells (118). However, in contrast to the
finding of Chen and co-workers, VPA did not inhibit GSK3β in vitro in the study of Hall
and co-workers, suggesting that inhibition of GSK3β by VPA may be indirect (118). The
inhibitory effect of VPA on GSK3β was further supported by the finding of increased
levels of GSK3β serine-9 phosphorylation in VPA-treated human neuroblastoma cells
(122). In addition, similar to lithium, VPA exerted behavioral effects as a result of
disrupting the AKT/GSK3 signaling pathway (123).
While the findings described above suggest that VPA inhibits GSK3β, this
outcome in not universally supported. In the report of Phiel and co-workers, VPA did not
affect the phosphorylation of tau protein by GSK3β in neuronal cells or the in vitro
phosphorylation of glycogen synthase peptide-2 (121). In addition, increased β-catenin
levels were observed in dorsal root ganglia cultures treated with lithium but not VPA
(17). Similar results were obtained in other studies (124,125). The variety of model
systems and methodologies used in these studies likely contributes to the discrepancy
in results, and further investigation is necessary to understand the effect of VPA on
GSK3.
2.3. HDAC inhibition and GSK3 activity
Therapeutic concentrations of VPA have been shown to inhibit histone
deacetylase (HDAC) (126) (127,128). Interestingly, HDAC inhibitors exhibit antidepressive effects in mouse models of depression (129,130). HDAC inhibition greatly
affects the transcription profile and alters cellular signaling, consequences that could
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potentially account for the therapeutic effects of VPA (131). For example, long-term
treatment with the HDAC inhibitor Cpd-60 led to significantly increased levels of Sgk1
expression in mouse brain (130). Up-regulation of Sgk1 was also reported in rodents
treated with lithium and other anti-depressants (132,133). Sgk1 encodes a protein
kinase that phosphorylates and inhibits GSK3β (134). As discussed previously, the
activity of GSK3 is negatively regulated by the AKT signaling pathway. VPA increased
the activation-associated phosphorylation of Akt and the inhibition-associated
phosphorylation of GSK3β (122). Two other HDAC inhibitors, TSA and sodium butyrate,
also mimicked the effect of VPA in activating Akt and inhibiting GSK3β, suggesting that
HDAC inhibition promotes GSK3β inhibition via the AKT pathway (122). Although the
discrepancy remains as to whether VPA directly affects GSK3 activity, as discussed
above, these findings suggest that VPA indirectly inhibits GSK3β by inhibiting HDAC,
which may underlie the anti-depressant effects of the drug.
2.4. Neurotrophic effects of GSK3 inhibition
Many studies have reported a loss of neuronal and glial cells in the brains of BD
patients (135-138), possibly due to increased apoptosis (139). GSK3 is a pro-apoptotic
enzyme, the activation of which facilitates apoptosis (140,141). Therefore, GSK3
inhibition may exert its neurotrophic and anti-bipolar effects by decreasing apoptosis of
neuronal cells in the brain. The reduction of intracellular GSK3β levels was shown to
protect neurons from amyloid-β induced neurotoxicity (142), while overexpression of
GSK3β induced caspase-3 dependent apoptosis in mouse neuronal cells (143).
Granulocyte-colony stimulating factor (G-CSF) is a neuroprotective growth factor that
antagonizes apoptosis by inhibiting GSK3β (144). The connection between altered
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GSK3 activity and apoptosis was further supported by the finding that several selective
GSK3 inhibitors and anti-bipolar drugs, including VPA and lithium, also provided
significant protection from apoptotic cell death (67,145-147). In a mouse model, VPA
was shown to exert an anti-apoptotic effect by up-regulating B-cell lymphoma 2 (Bcl-2)
expression (148). VPA and lithium increased intracellular Bcl-2 levels in human
neuronal cells (149). VPA also inhibited apoptosis in human endothelial cells by
preventing Bcl-2 ubiquitination (150). Furthermore, lithium prompted neural precursor
cell proliferation via GSK-3β-NF-AT (nuclear factor of activated T cells) signaling (151).
GSK3 inhibition exhibited neuroprotective effects against excitotoxicity (152). These
studies suggest that VPA and lithium may exert their therapeutic effects by promoting
survival and proliferation of neuronal cells as a consequence of GSK3 inhibition.
In addition to promoting anti-apoptotic signaling, inhibition of GSK3β leads to
activation of the Wnt pathway and up-regulation of β-catenin (153-155). As a
transcription factor, β-catenin plays an important role in regulating neuronal connectivity,
which is critical for diverse neuronal functions (156). Some evidence suggests that
increased intracellular β-catenin is a potential therapeutic strategy of BD treatment.
L803-mts, a selective GSK3β inhibitor with anti-depressive efficacy, caused elevated βcatenin expression in mouse hippocampus (113). Overexpression of β-catenin in mouse
brain and lithium treatment induced similar behavior changes, including decreased
immobility time in the forced swim test (157). Furthermore, overexpression of β-catenin
inhibited amphetamine-induced hyperlocomotion, mimicking the anti-manic effect of
lithium. A recent study using induced pluripotent stem cell (iPSC) lines derived from BD
patients indicated abnormal neurogenesis and expression of genes that are critical for
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Wnt signaling (158). The proliferation defect in BD-iPSC cells was rescued by GSK3
inhibition. Together, these findings suggest that the therapeutic efficacy of GSK3β
inhibition in BD may occur by upregulating β-catenin. Targeting Wnt/β-catenin signaling
may be a promising strategy for BD treatment.
In summary, GSK3 may play a pivotal role in the therapeutic mechanisms of
bipolar disorder therapy. Altered GSK3 activity and protein levels were observed in BD
patients. Decreasing GSK3 by genetic ablation or treatment with inhibitors mimics the
mood-stabilizing effect of anti-bipolar drugs in animal behavior studies. In addition,
several studies reported that VPA inhibits GSK3 enzymatic activity. These findings
suggest that GSK3 inhibition, similar to inositol depletion, is a common effect of
structurally disparate mood-stabilizing drugs.
3. A unified model of inositol depletion and GSK3 inhibition
While inositol depletion and GSK3 inhibition may appear to be unrelated, we
suggest that they may constitute components of a single mechanism. Studies have
shown that GSK3 is required for optimal inositol biosynthesis in yeast (159). Yeast cells
lacking GSK3 (gsk3△ cells) exhibit multiple features of inositol depletion: intracellular
inositol levels in gsk3△ are 70% lower than in WT cells; the growth rate of gsk3△ cells in
I - medium is significantly slower than that of WT cells; and the mutant exhibits
decreased MIPS enzymatic activity (159). These findings indicate that GSK3 is required
for optimal inositol homeostasis in yeast. As discussed above, MIPS activity is regulated
by phosphorylation. Interestingly, a potential GSK3 phosphorylation site has been
identified in yeast MIPS (Fig. 1-2). Mutation of this residue results in alteration of MIPS
enzymatic activity, suggesting a potential regulatory mechanism of MIPS by GSK3
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Figure 1-2. A potential GSK3 phosphorylation site in MIPS. Both human and yeast
MIPS contain a potential GSK3 phosphorylation site (serine-279 of human MIPS and
serine-296 of yeast MIPS) within a six-amino acid region of identity (64).
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through phosphorylation (64). Strikingly, a sequence identical to the putative yeast
GSK3 phosphorylation site is present in human MIPS (64). Mutation of this site in the
human enzyme affected MIPS activity similar to the yeast mutant enzyme. We
speculate that regulation of MIPS activity by phosphorylation of this site may be a
conserved mechanism of regulation of inositol synthesis. Interestingly, inositol synthesis
in neuronal cells was shown to affect GSK3 activity. Knockdown of the ISYNA1 gene,
which encodes MIPS in mammalian cells, led to inactivation of GSK3α by increasing
inhibitory phosphorylation of Serine-21 (160), suggesting that GSK3 and inositol
synthesis may be coordinately regulated.
GSK3 may also regulate inositol synthesis by affecting metabolism of glucose 6phosphate (G6P), which is the substrate for inositol de novo synthesis. GSK3 controls
the conversion of glucose to glycogen by regulating glycogen synthase activity (99). The
inhibition of GSK3 in hepatic cells reduces expression of glucose-6-phosphatase and
phosphoenolpyruvate carboxykinase, which regulate gluconeogenesis (161). In addition,
expression of phosphoglucomutase 2 (PGM2), which catalyzes the interconversion of
glucose-1-phosphate and glucose-6-phosphate (162), requires GSK3 activity (163).
Interestingly, lithium inhibits PGM2 (164), whereby it may also affect intracellular G6P
production. These findings suggest that GSK3 may regulate inositol synthesis by
controlling the availability of G6P. It will be of great importance to determine if VPA,
lithium and GSK3 inhibition affect the rate of glucose uptake and G6P production.
The model shown in Fig. 1-3 unifies both inositol depletion and GSK3 inhibition in
the following hypothesis. VPA induces inositol depletion by decreasing MIPS activity
through inhibition of GSK3. As a major component of intracellular signaling molecules,
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Figure 1-3. Model: Dual effects of VPA and lithium on inositol depletion and GSK3
inhibition contribute to mood stabilization. GSK3 is required for optimal de novo
synthesis of inositol in yeast. VPA (upper panel) indirectly inhibits MIPS, the rate limiting
enzyme of inositol de novo synthesis, possibly by inhibiting GSK3, thereby reducing
intracellular inositol. Lithium (lower panel) depletes inositol by inhibiting IMPase, and
inhibits GSK3 by multiple mechanisms. In addition to inhibition of MIPS activity, GSK3
inhibition may also affect metabolism of G6P, the substrate for inositol de novo
synthesis. Inositol depletion leads to perturbation of numerous cellular functions, some
of which are associated with mood stabilization. Inhibition of GSK3 affects cells in
numerous ways, some of which are neurotrophic and may contribute to mood
stabilization.
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inositol is involved in the regulation of PI synthesis, protein secretion and many other
cellular functions (18,19,165). Alteration of inositol metabolism affects expression of
hundreds of genes and causes numerous cellular consequences (31,166), among
which are those that may lead to mood stabilization. VPA-induced GSK3 inhibition also
exerts neurotrophic effects by reducing apoptosis of neuronal cells through upregulation of anti-apoptotic factors, and by up-regulation of β-catenin. Lithium also
causes dual effects of GSK3 inhibition as well as inositol depletion by inhibition of
IMPase. The inter-relationship between inositol depletion and GSK3 inhibition may
contribute to the therapeutic effects of VPA and lithium.
4. Conclusion
Although the therapeutic mechanisms of VPA and lithium are not understood,
both inositol depletion and GSK3 inhibition are common outcomes of treatments by
these structurally dissimilar drugs and may play a role in their therapeutic effects. We
speculate that VPA- and lithium-induced GSK3 inhibition may inhibit MIPS enzymatic
activity by mediating the inhibitory phosphorylation of MIPS, the rate limiting enzyme of
de novo inositol synthesis, resulting in depletion of intracellular inositol.
Project outline
The goal of the studies presented in this thesis was to elucidate new
mechanisms of regulation of inositol metabolism, and to understand the physiological
effects of inositol-depleting compounds. Three independent projects focusing on the
regulation of inositol synthesis are described in the following chapters. The
interrelationships of these projects are demonstrated in Figure 1-4.
The studies in Chapter 2 demonstrate that Mck1 is the yeast GSK3β homolog
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Figure 1-4. Project outline. Chapter 2 demonstrates that Mck1 regulates the rate of
inositol synthesis and mediates VPA-induced MIPS inhibition. Chapter 3 characterizes
IP6K1 as a novel negative regulator of inositol synthesis in mammalian cells. IP6K1
inhibits expression of the mammalian MIPS-encoding gene Isyna1 (mIno1). Studies in
Chapter 4 show that VPA depletes intracellular G-6-P, possibly by inhibiting expression
of hexose transporter genes. VPA induces Mig1 nuclear translocation, which represses
hexose transporter gene expression.
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required for optimal synthesis of inositol. mck1∆ exhibited multiple features of inositol
depletion, which could be rescued by supplementation of inositol. Intracellular inositol
levels and MIPS activity were also decreased in mck1∆ cells. VPA requires Mck1 to
inhibit MIPS enzymatic activity. Taken together, Mck1 mediates VPA-induced MIPS
inhibition, which thereby leads to inositol depletion.
In Chapter 3, I identified and characterized IP6K1 as a novel regulator of inositol
synthesis in mammalian cells. Ip6k1 ablation led to profound changes in DNA
methylation and expression of mIno1, which encodes the rate-limiting enzyme inositol3-phosphate synthase. Interestingly, IP6K1 preferentially bound to the phospholipid
phosphatidic acid, and this binding was required for IP6K1 nuclear localization and the
regulation of mINO1 transcription. This is the first demonstration of IP6K1 as a novel
negative regulator of inositol synthesis in mammalian cells.
Chapter 4 describes the effect of VPA on G-6-P metabolism and expression of
hexose transporter genes. This study demonstrated that chronic VPA treatment
depletes intracellular G-6-P. VPA also inhibits expression of HXT2, HXT3, HXT4, and
HXT4, which encode glucose transporters, possibly by activating Mig1-mediated
transcription repression. These findings suggest that VPA depletes intracellular G-6-P,
at least partially, by decreasing glucose uptake. Therefore, VPA-induced perturbation of
G-6-P metabolism may affect downstream pathways, including inositol synthesis and
glycolysis.
While this dissertation describes exciting findings on the regulation of inositol
synthesis, many interesting questions remain. These questions are presented in
Chapter 5 as topics for future study.
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CHAPTER 2 MCK1 REGULATES THE RATE OF INOSITOL SYNTHESIS BY
INCREASING MYO-INOSITOL-3-PHOSPHATE SYNTHASE (MIPS) ACTIVITY IN
SACCHAROMYCES CEREVISIAE
INTRODUCTION
Myo-inositol
phosphoinositides,

is

the
inositol

precursor

of

phosphates,

all

inositol
inositol

compounds,

including

sphingolipids,

and

glycosylphosphatidylinositols. Inositol compounds are critical for many key cellular
processes (20,27,167,168), and are essential for the viability of eukaryotes. The pivotal
role of inositol is underscored by the link between perturbation of inositol metabolism
and human neurological disorders(18). In addition, inositol depletion was proposed as
the therapeutic effect of valproic acid (VPA) and lithium. Therefore, elucidating how
inositol synthesis is regulated is of obvious importance to understanding cell function
and the pathologies underlying many illnesses.
The de novo synthesis of inositol has been well characterized in the yeast
Saccharomyces cerevisiae. Inositol is synthesized de novo from glucose-6-phosphate
(G-6-P) in a two-step reaction. G-6-P is first converted to inositol-3-phosphate by the
rate-limiting enzyme myo-inositol-3-phosphate synthase (MIPS), which is encoded by
INO1 (8-10,169,170). Then inositol-3-phosphate is dephosphorylated to myo-inositol
(12). Inositol synthesis is tightly regulated at the level of transcription of INO1 in
response to extracellular inositol levels (171,172). Furthermore, both yeast and human
MIPS are phosphoproteins, whose activities are regulated by phosphorylation (63,64).
Yeast cells treated with VPA at concentrations used therapeutically exhibited decreased
MIPS activity (59), and the inhibition of MIPS activity was indirect and not observed in
vitro (60). VPA induced MIPS inhibition was also reported in human brain tissue (61).
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VPA has also been shown to increase phosphorylation of MIPS (64). Therefore, VPA
possibly inhibits MIPS via an as yet unidentified kinase.
A clue to the mechanism underlying VPA-induced MIPS inhibition came from the
finding that yeast GSK3 homologs are required for optimal de novo synthesis of inositol.
Yeast gsk3∆ cells exhibited multiple features of inositol depletion, including decreased
growth in I- media, decreased intracellular inositol levels, and increased sensitivity to the
inositol-depleting drug VPA (159). As a serine/threonine kinase, GSK3 is involved in
the regulation of many cellular functions (101-103). Two isoforms of GSK3 exist in
mammalian cells, GSK3α and GSK3β (104,105). These isoforms exhibit 98% identity in
the amino acid sequences of their kinase domains (105). GSK3β, the predominant form
in the brain, regulates more than 40 proteins in many cell signaling pathways, some of
which play a role in BD as well as Alzheimer’s disease and cancer (102,103,108,109).
The inhibition of GSK3β activity contributes to alleviation of BD symptoms in animal
models (110,113-116). Interestingly, a potential GSK3 phosphorylation site was
identified in both yeast and human MIPS, suggesting that GSK3 regulates MIPS
phosphorylation (64). Furthermore, VPA has been shown to inhibit GSK3 in several
studies (117-120). Therefore, GSK3 possibly mediates VPA-induced MIPS inhibition,
which leads to inositol depletion.
Four genes encode yeast GSK3 homologs, MCK1, MDS1, MRK1 and YGK3
(173). The yeast gsk3∆ strain is a quadruple null mutant in which all four genes are
knocked out. The functions of these genes are not well understood. More importantly, it
is not clear which gene is involved in the regulation of yeast inositol synthesis.
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In this report, we demonstrate that MCK1 encodes the yeast GSK3 homolog
required for the optimal synthesis of inositol. mck1∆ cells exhibited decreased growth in
the presence of VPA, which was rescued by the supplementation of inositol. The
intracellular inositol levels, MIPS activity, and in vivo rate of inositol synthesis were
decreased in mck1∆ cells. VPA treatment did not reduce MIPS activity in mck1∆ cells,
indicating that Mck1 mediates VPA-induced MIPS inhibition. Interestingly, the triple-null
mutant (mds∆1mrk1∆ygk3∆) did not exhibit any feature of inositol depletion, suggesting
that inositol depletion observed in gsk3∆ cells is due to ablation of the MCK1 gene. This
study demonstrates for the first time that the yeast GSK3 homolog Mck1 regulates
inositol synthesis by increasing MIPS activity.
MATERIALS AND METHODS
Yeast strains
All strains used in this study were in the W303 background. The WT strain was
crossed with the gsk3△ strain for the generation of haploid spores. The isogenic gsk3
mutant strains used in this study were selected from haploid spores. The GSK3
genotype of each mutant strain generated in this study was confirmed by PCR. To
determine MIPS enzymatic activity, I constructed yeast strains that harbor a gene
encoding His-Xpress tagged MIPS in their genomes. The INO1 gene in each strain was
first knocked out with a KanMX cassette, which was replaced by an N-terminal HisXpress tagged INO1 cassette cloned from pRD-INO1 plasmid, which was generously
provided by Dr. Rania Deranieh (64). The HA-MCK1 strain, which expresses a Cterminal HA tagged Mck1, was constructed for the purpose of protein purification. The
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stop codon of the MCK1 gene was replaced by a sequence that coding for the HA tag
and a KanMX cassette.
Growth media
Yeast cells were grown at 30°C or 37°C in synthetic complete (SC) medium,
which contained glucose (2% w/v), adenine (20 mg/liter), arginine (20 mg/liter), histidine
(20 mg/liter), methionine (20 mg/liter), tryptophan (20 mg/liter), leucine (60 mg/liter),
lysine (200 mg/liter), threonine (300 mg/liter), ammonium sulfate (0.2% w/v), inositolfree Difco vitamin mix, vitamin-free yeast base, plus agar (2% w/v) for solid medium.
Inositol (75 μM) and VPA (1 mM) were added separately as indicated.
Measurement of intracellular inositol and G-6-P levels
Intracellular inositol levels were determined using the method of Maslanski and
Busa with modification (174). In brief, yeast cells were lysed in dH2O containing 1X
protease inhibitor by vortexing with acid-washed glass beads at 4°C. Cell extracts were
mixed with 7.5% perchloric acid and centrifuged at 10,000 g for 10 min at 4°C.
Supernatants were collected and titrated with ice cold KOH to pH 7. Samples were
clarified by centrifugation and loaded onto columns containing 1 ml AG 1-X8 resin/H20
(1:1) mixture. Inositol was eluted with 5 ml dH2O, eluates were dried in an oven at 70°C
and stored at -80°C. Prior to assay, samples were dissolved in dH2O. Inositol content in
samples was measured as described previously (62).
To determine intracellular G-6-P levels, yeast cells were washed twice with icecold dH2O and lysed in dH2O containing 1X protease inhibitor by vortexing with acidwashed glass beads at 4°C. Cell extracts were mixed with 1 ml ice cold MeOH:CHCl3
(2:1), vortexed, and stored at -20°C for 2 h. Samples were then mixed with extraction
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solution (50% MeOH, 4 mM tricine pH 5.4) and centrifuged at 18,000 g for 10 min. The
upper phase was collected and kept on ice. The lower chloroform phase was extracted
again with extraction solution. Upper phases from both extractions were combined,
dried with a speedvac, and stored at -80°C. Prior to assay, samples were dissolved in
dH2O. G-6-P content in samples was measured by the enzyme-coupled fluorescence
assay developed by Zhu et al. with modification (175).
MIPS activity assay
Cells expressing His-Xpress tagged MIPS were grown to the early stationary
phase and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 0.6 M sorbitol, 0.3 M NaCl, 1X
protease inhibitor and 1X phosphatase inhibitor) by vortexing with acid-washed glass
beads at 4°C. MIPS protein was purified from cell extracts using PureProteome™ Nickel
Magnetic Bead System (Millipore). Purified MIPS protein was dialyzed (1 mM Tris
acetate pH 8.0, 0.05 M dithiothreitol , 0.025X protease inhibitor and 0.1X phosphatase
inhibitor) and concentrated with Amicon Ultra-0.5 Centrifugal Filter system (Millipore).
MIPS protein concentration was determined by Bradford assay. Enzymatic activity of 3
μg purified MIPS was determined by enzyme-coupled colorimetric assay (176).
In vitro phosphorylation of MIPS
HA-Mck1 was purified from the HA-MCK1 strain by immunoprecipitation. Histagged MIPS was purified as described previously. 4 μg MIPS was incubated with 5 μg
HA-Mck1 in reaction buffer (20 mM Tris-Cl pH7.5, 200 mM ATP, 1.5 μCi
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P-ATP, 10

mM MgCl2, 5 mM DTT) for 30 min in a 1.5 ml tube. 10 μM solution from the reaction
tube was spotted on a piece of P81 filter paper, which was washed three times in 100
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ml 0.75% phosphoric acid. MIPS phosphorylation levels were determined by
autoradiography.
Measurement of the rate of inositol de novo synthesis in vivo
Cells were grown in SC I+ medium to the mid log phase, washed twice with dH2O,
transferred to SC I- medium, and incubated for 1 h or 3 h. [U-13C]glucose was added to
a final concentration of 0.2%. After 15 min, cells were harvested and lysed in dH2O
containing 1X protease inhibitor by vortexing with acid-washed glass beads at 4°C.
Soluble protein in cell extract was reduced by filtration using the Amicon Ultra-0.5
Centrifugal Filter system (Millipore).
determined by LC-MS.
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C labeled I-3-P and inositol in samples were
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Table 2-1. Strains used in this study.
Strain

Genotype

Source

W303

MATa his3, leu2, ura3, trp1, ade2

Andoh T. (173)

mck1∆

MATα his3, leu2, ura3, trp1, ade2, mck1::TRP1

This study

mrk1∆

MATα his3, leu2, ura3, trp1, ade2, mrk1

This study

mds1∆

MATα his3, leu2, ura3, trp1, ade2, mds1::HIS3

This study

ygk3∆

MATa his3, leu2, ura3, trp1, ade2, ygk3::LEU2

This study

gsk3∆

MATa his3, leu2, ura3, trp1, ade2, mck1::TRP1, mrk1,

Andoh T. (173)

mds1::HIS3, ygk3::LEU2
WY234

MATa his3, leu2, ura3, trp1, ade2, mrk1, mds1::HIS3,

This study

ygk3::LEU2
His-Xpress WT

MATa his3, leu2, ura3, trp1, ade2, INO1-HIS-XPRESS

This study

His-Xpress mck1∆

MATα his3, leu2, ura3, trp1, ade2, mck1::TRP1,

This study

INO1-HIS-XPRESS
His-Xpress mrk1∆

MATα his3, leu2, ura3, trp1, ade2, mrk1, INO1-HIS-XPRESS

This study

His-Xpress mds1∆

MATα his3, leu2, ura3, trp1, ade2, mds1::HIS3,

This study

INO1-HIS-XPRESS
His-Xpress ygk3∆

MATa his3, leu2, ura3, trp1, ade2, ygk3::LEU2,

This study

INO1-HIS-XPRESS
His-Xpress gsk3∆

MATa his3, leu2, ura3, trp1, ade2, mck1::TRP1, mrk1,

This study

mds1::HIS3, ygk3::LEU2, INO1-HIS-XPRESS
His-Xpress WY234

MATa his3, leu2, ura3, trp1, ade2, mrk1, mds1::HIS3,

This study

ygk3::LEU2, INO1-HIS-XPRESS
HA-MCK1

MATa his3, leu2, ura3, trp1, ade2, MCK1-HA

This study
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RESULTS
mck1△ and gsk3△ cells exhibit similar features of inositol depletion
Our lab has previously shown that GSK3 genes are required for optimal inositol
biosynthesis in yeast (159). To identify the yeast GSK3 gene involved in the regulation
of inositol synthesis, I constructed single, double and triple gsk3 mutants that are
isogenic to the gsk3∆ quadruple mutant. Consistent with our previous study, the growth
of gsk3△ cells was greatly decreased at elevated temperatures (159). Among four gsk3
single mutants, mck1△ was the only one that exhibited decreased growth at elevated
temperatures (Fig. 2-1). At 37°C, mck1△ cells grew slightly slower than WT, while the
other three single mutants grew at a rate similar to WT. The decreased growth of
mck1△ was further exacerbated at 38°C. Interestingly, the mrk1△mds1△ygk3△ triple
mutant, which retained MCK1 in the genome, grew slightly better than WT at 38°C.
These findings suggest that MCK1 is required for optimal growth in I- conditions at
elevated temperatures. Interestingly, the triple deletion of MRK1, MDS1, and YGK1
genes benefited cell growth at elevated temperature in I- conditions.
VPA inhibits the growth of inositol auxotrophic strains by depleting intracellular
inositol. We determined VPA sensitivity of gsk3 mutants. Both mck1△ and gsk3△ cells
exhibited decreased growth in the presence of VPA, which was rescued by
supplementation of inositol (Fig. 2-1). All other mutants grew as well as WT, suggesting
that deletion of the MCK1 gene accounts for VPA sensitivity.
To determine the effects on inositol metabolism of deleting each GSK3 gene,
intracellular inositol levels were measured in gsk3 mutants. Consistent with previous
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Figure 2-1. mck1△ and gsk3△ cells exhibit similar phenotypes. WT and gsk3
mutant cells were serially diluted and spotted on SC plates supplemented with VPA (1
mM) and inositol (75 μM) as indicated. Plates were incubated at the indicated
temperatures for 3 days. mck1△ and gsk3△ cells exhibit decreased growth at elevated
temperatures and in the presence of VPA.
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studies (159), inositol levels were significantly decreased in gsk3△ cells (Fig. 2-2). The
mck1△ strain was the only gsk3 mutant that exhibited decreased intracellular inositol
levels compared to WT. A nearly 50% drop in intracellular inositol was observed in
mck1△ cells, similar to the 60% decrease seen in gsk3△ cells. The other three single
mutants exhibited levels of inositol similar to WT. Interestingly, inositol levels were 40%
higher in the mrk1△mds1△ygk3△ triple mutant, suggesting that one or more of these
genes inhibits inositol synthesis. In summary, deletion of MCK1 causes multiple
features of inositol depletion, which can account for the defects observed in gsk3△ cells.
Mck1 regulates MIPS activity
We hypothesized that decreased intracellular inositol levels in mck1 △ cells
resulted from decreased activity of MIPS, the rate-limiting enzyme of inositol synthesis.
To test this, I purified MIPS from cells expressing His-Xpress tagged protein. Compared
to WT, a 50% decrease in MIPS activity was observed in mck1△ cells (Fig. 2-3). The
other three gsk3 single mutants and the mrk1△mds1△ygk3△ triple mutant exhibited WT
MIPS activity. I further studied the effects of VPA on MIPS activity in WT, mck1△ and
gsk3△ cells. As shown in Fig. 2-4, VPA caused more than a 40% decrease in MIPS
activity in WT cells. However, VPA treatment did not significantly decrease MIPS activity
in mck1△ and gsk3△ cells. These findings suggest that MCK1 is the only GSK3 gene
required for normal MIPS activity, and that Mck1 mediates VPA-induced MIPS inhibition.
Inositol depletion in mck1△ cells possibly resulted from MIPS inhibition. However, Mck1
did not phosphorylate MIPS in vitro (Fig. 2-5), suggesting that Mck1 indirectly regulates
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Figure 2-2. Decreased intracellular inositol levels in mck1△ and gsk3△ cells. Cells
were grown in SC medium to the early stationary phase. Intracellular inositol levels were
determined as described in “Materials and Methods”. Values shown are mean ± SEM
(n=9).
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Figure 2-3. MIPS activity is decreased in mck1△ cells. Cells expressing His-Xpress
tagged MIPS were grown in SC medium to the early stationary phase. Enzymatic
activity of MIPS protein purified from cell extracts was determined as described in
“Materials and Methods”. Values shown are mean ± SEM (n=6).
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Figure 2-4. VPA does not decrease MIPS activity in mck1△ and gsk3△ cells.
Cells expressing His-Xpress tagged MIPS were grown in SC medium to the mid log
phase and treated with 1 mM VPA for 3 h. MIPS activities were determined as
described in “Materials and Methods”. Values shown are mean ± SEM (n=6).
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Figure 2-5. Mck1 does not phosphorylate MIPS in vitro. HA tagged Mck1 was
purified from HA-MCK1 cells by immunoprecipitation. His-Xpress tagged MIPS was
purified as described previously. Mck1 and MIPS were incubated in reaction buffer with
32
P-ATP. MIPS phosphorylation was determined by autoradiography.
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MIPS phosphorylation, or that Mck1 requires co-factors to target MIPS in physiological
conditions. Another possibility is that the HA tag disrupts Mck1 conformation, and
results in catalytic inactivity.
Surprisingly, WT and gsk3△ cells exhibited similar levels of MIPS activity.
However, the in vitro MIPS assay does not reflect the rate of inositol synthesis in yeast
cells in physiological conditions. Therefore, I developed an assay to determine the rate
of inositol synthesis in vivo.
Mck1 regulates rate of inositol de novo synthesis
In collaboration with Dr. Krishna Rao Maddipati, WSU Lipidomics Core director, I
developed a novel method to measure the rate of inositol synthesis in vivo. In brief, cells
grown in I+ medium were washed, transferred to I- medium, and grown for 1-3 h. [U13

C]glucose was added to the media to allow synthesis of

13

C labeled inositol-3-

phosphate and inositol, which were detected by LC-MS. As seen in Fig. 2-6A, mck1△
and gsk3△ cells exhibited significantly lower levels of [U-13C]inositol-3-phosphate
compared to WT cells after 1 h of labeling. The differences in inositol-3-phosphate
levels reached a maximum at 2 h. WT, mck1△ and gsk3△ cells exhibited similar levels
of [U-13C]inositol at the 1 h time point (Fig. 2-6B). At 3 h, levels of [U-13C]inositol were
significantly decreased in mck1△ and gsk3△ cells. However, mck1△ and WT cells
exhibited similar levels of [U-13C]inositol. The reason for this is not clear. These results
indicate that Mck1 is required for optimal rate of inositol synthesis in vivo.
Mck1 possibly regulates MIPS by controlling glucose 6-phosphate availability
Mck1 may regulate MIPS activity by at least three mechanisms, including
regulation of MIPS phosphorylation, MIPS protein level, and controlling the availability of
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Figure 2-6. Rates of inositol-3-phosphate and inositol synthesis are decreased in
gsk3△ and mck1△ cells. Cells were cultured in SC medium supplemented with 75 μM
inositol to the mid log phase and transferred to SC I- media for 1-3 h. [U-13C]glucose
was then added at a final concentration of 0.2% and cells were incubated for 15 min.
Levels of 13C labeled I-3-P (A) and inositol (B) in cell extracts were determined by LCMS. Values shown are mean ± SEM (n=6).
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glucose 6-phosphate (G-6-P), the substrate of MIPS. As described previously, Mck1
does not phosphorylate MIPS in vitro. In addition, MIPS levels are not decreased in
mck1△ and gsk3△ cells (data not shown). To address the third possibility, we measured
intracellular G-6-P levels in mck1△ and gsk3△ cells. Compared to WT, the intracellular
G-6-P levels were 80% and 70% lower in gsk3△ and mck1△ cells, respectively (Fig. 27). In addition, intracellular G-6-P levels were 75% lower in WT cells treated with VPA
(shown and discussed in Chapter 4). These results suggest that Mck1 regulates MIPS
by controlling G-6-P levels, and that VPA-induced inositol depletion is possibly a
combined outcome of both G-6-P depletion and MIPS inhibition.
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Figure 2-7. Intracellular G-6-P levels are decreased in mck1△ and gsk3△ cells.
Cells were grown in SC medium to the early stationary phase. Intracellular G-6-P levels
were determined as described in “Materials and Methods”. Values shown are mean ±
SEM (n≥8).
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DISCUSSION
The current study discovered for the first time that the yeast GSK3 gene MCK1
regulates inositol synthesis. Major findings of this study are as follows. 1) Mck1 is
required for optimal intracellular inositol levels and MIPS activity. 2) VPA inhibits MIPS
enzymatic activity via Mck1. 3) The rate of inositol synthesis is decreased in mck1△ and
gsk3△ cells in vivo. 4) mck1△ and gsk3△ cells exhibit decreased intracellular G-6-P
levels. These findings identify Mck1 as a regulator of inositol de novo synthesis in yeast.
Among the four single mutant strains mck1△, mrk1△, mds1△, and ygk3△, only
mck1△ cells exhibited decreased growth at elevated temperatures, as observed in
gsk3△ cells (Fig. 2-1), while mrk1△, mds1△ and ygk3△ cells grew as WT. In addition,
mck1△ and gsk3△ exhibit severely decreased growth in the presence of VPA. The other
three gsk3 single mutants grew normally compared to WT. The addition of inositol to
growth media rescued sensitivities to VPA in mck1△ and gsk3△ cells. VPA has been
shown to deplete intracellular inositol and inhibits the growth of inositol auxotrophs
(60,64,159). These findings suggest that mck1△ cells are defective in inositol synthesis.
Therefore, exogenous inositol must be provided to maintain normal levels of inositol in
these cells. In fact, the intracellular inositol levels in mck1△ cells decreased to levels
similar to those of gsk3△ cells (Fig. 2-2). The other three single mutants, mrk1△, mds1△
and ygk3△, exhibited normal inositol levels. In addition, the simultaneous deletion of
MRK1, MDS1 and YGK3 did not result in any features of inositol depletion, suggesting
that only MCK1 was required for optimal inositol levels.
MIPS purified from mck1△ cells exhibited decreased enzymatic activity (Fig. 2-3),
suggesting that MCK1 is required for optimal MIPS activity. MIPS is a phosphoprotein,
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and the phosphorylation of MIPS has been reported to regulate its enzymatic activity
(63,64). Yeast MIPS contains a potential GSK3 phosphorylation site, Ser-296.
Phosphorylation of this site up-regulates MIPS activity (64), which is consistent with our
finding that Mck1 positively regulates MIPS activity. On the other hand, phosphorylation
of MIPS Ser-184, which is a potential PKA phosphorylation site, downregulates MIPS
activity (64). Interestingly, Mck1 has been reported to inhibit PKA activity in yeast (177).
Therefore, MCK1 ablation may contribute to increased phosphorylation on Ser-184.
These findings suggest that MIPS inhibition in mck1△ cells results from decreased
activating phosphorylation of Ser-296 and increased inhibitory phosphorylation of Ser184. However, Mck1 did not phosphorylate MIPS in vitro (Fig. 2-5), suggesting that
Mck1 may need co-factors to phosphorylate MIPS in vivo, or that the effect of Mck1 is
indirect, e.g., via a kinase activated by Mck1. It is also possible that the HA tag inhibits
Mck1 catalytic activity. VPA has been shown to inhibit mammalian GSK3 in several
studies (117-120). As a yeast GSK3 homolog, Mck1 is a possible target of VPA. In
support of this hypothesis, VPA did not inhibit MIPS activity in mck1△ and gsk3△ cells
(Fig. 2-4). PKA, AKT, and PKC signaling pathways are also affected by VPA treatment
(65-67). Further studies are required to determine if these pathways mediate VPAinduced MIPS inhibition. Taken together, these studies indicate that Mck1 mediates
VPA-induced MIPS inhibition by regulating MIPS phosphorylation.
We determined rates of inositol synthesis under physiological conditions in WT,
mck1△ and gsk3△ cells. As shown in Fig. 2-6, rates of synthesis of inositol-3-phosphate
and inositol were decreased in mck1△ cells, which is consistent with decreased MIPS
activity and decreased inositol levels observed in mck1△ cells. Therefore, the
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decreased rate of inositol synthesis in mck1△ cells is caused, at least in part, by
decreased MIPS activity. Surprisingly, rates of I-3-P and inositol synthesis in vivo, but
not MIPS activity determined in vitro, were decreased in gsk3△ cells, which suggested
the involvement of a second level of regulation of inositol synthesis. Previous studies
have shown that the glycolytic intermediate dihydroxyacetone phosphate (DHAP) is a
strong inhibitor of MIPS (178,179). The accumulation of intracellular DHAP leads to
inositol auxotrophy (178), suggesting a link between perturbation of glycolysis and
inhibition of inositol de novo synthesis. Furthermore, Mck1 negatively regulates the
activity of pyruvate kinase (177,180), which catalyzes the final and irreversible step of
glycolysis in yeast (181). The levels of pyruvate kinase influence the glycolytic flux in
yeast cells (182), which suggests that increased pyruvate kinase activity in mck1△ cells
may increase the flux of G-6-P into glycolysis. In fact, the intracellular G-6-P levels were
significantly decreased in mck1△ and gsk3△ cells (Fig. 2-7). The limited availability of
G-6-P may contribute to the decreased rates of inositol synthesis in mck1△ and gsk3△
cells. It is possible that the regulation of inositol de novo synthesis is regulated at the
level of G-6-P flux.
This study demonstrates for the first time that the yeast GSK3 homolog MCK1 is
required for optimal rate of inositol synthesis. mck1△ cells exhibit multiple features of
inositol depletion and decreased intracellular G-6-P levels. In addition, Mck1 mediates
VPA-induced MIPS inhibition. Future studies should focus on the elucidation of potential
mechanisms by which Mck1 regulates MIPS activity.
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CHAPTER 3 INOSITOL HEXAKISPHOSPHATE KINASE 1 (IP6K1) REGULATES
INOSITOL SYNTHESIS IN MAMMALIAN CELLSINTRODUCTION
The work described in this chapter has been published in Yu, W., Ye, C., and
Greenberg, M. L. (2016) Inositol Hexakisphosphate Kinase 1 (IP6K1) Regulates Inositol
Synthesis in Mammalian Cells. The Journal of biological chemistry 291, 10437-10444
(183) .
INTRODUCTION
Inositol is a ubiquitous six-carbon cyclitol that is essential for viability of
eukaryotic cells.

Myo-inositol, physiologically the most important stereoisomer of

inositol, is the precursor of all inositol compounds, including phosphoinositides, inositol
phosphates,

inositol

sphingolipids,

and

glycosylphosphatidylinositols.

Inositol

compounds are essential for gene expression (167), trafficking (27), signal transduction
(20) and membrane biogenesis (168). The crucial role of inositol is underscored by the
link between perturbation of inositol metabolism and human disorders (18). Therefore,
elucidating the mechanisms underlying the control of inositol homeostasis is expected
to have important implications for understanding cell function and the pathologies
underlying many illnesses.
While cellular inositol can be obtained from the extracellular environment or by
recycling inositol lipids (7,23), the de novo synthesis of inositol is essential for inositol
homeostasis and cellular proliferation when environmental inositol is limiting (160,184).
Inositol synthesis is a two-step reaction in which glucose-6-phosphate (G6P), the
branch point metabolite for glycolysis, the pentose phosphate pathway, and inositol
synthesis, is converted to inositol-3-phosphate, which is dephosphorylated to inositol.
The first and rate-limiting step of inositol synthesis is catalyzed by inositol-3-phosphate
synthase (8-10,169,170). Significantly high levels of inositol are found in brain tissue,
which has limited access to exogenous inositol (14), suggesting that de novo synthesis
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of inositol is critical for normal brain function. Importantly, alterations in inositol
metabolism have been associated with bipolar disorder and Alzheimer’s disease
(18,37,185).
Despite its importance, little is known about the regulation of inositol synthesis in
mammals. In contrast, the regulation of inositol synthesis has been well-characterized in
the budding yeast Saccharomyces cerevisiae. Inositol synthesis in yeast is regulated at
the level of transcription of INO1 (171,172), the gene that codes for inositol-3-phosphate
synthase, and by phosphorylation of the Ino1 protein (64). INO1 expression is controlled
by the transcriptional repressor Opi1 in response to inositol and phosphatidic acid (PA)
levels (56). Opi1 is stabilized by physically interacting with PA on the endoplasmic
reticulum (ER) membrane. When inositol is limiting, PA levels are increased, Opi1
remains in the ER, and INO1 transcription is derepressed to increase inositol synthesis.
When inositol levels are abundant, PA is rapidly consumed for phosphatidylinositol
synthesis, Opi1 is released from the ER and translocates into the nucleus, where it
represses INO1 transcription resulting in decreased inositol synthesis. We have recently
demonstrated that transcription of INO1 in yeast is regulated by the synthesis of inositol
pyrophosphates, as INO1 transcription requires the Kcs1-catalyzed synthesis of
diphosphoinositol tetrakisphosphate (PP-IP4) (167).
In contrast to inositol synthesis in yeast, transcription of Isyna1 (the mammalian
homolog of yeast INO1, which we refer as mINO1 in this report), is not regulated in
response to inositol (160,186). However, in the current study, we demonstrate for the
first time that inositol synthesis in mouse embryonic fibroblast (MEF) cells is regulated
by inositol pyrophosphate. Knockout of inositol hexakisphosphate kinase IP6K1 [which
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catalyzes the formation of pyrophosphate at position five of inositol pentakisphosphate
/inositol hexakisphosphate to generate 5PP-IP4/5PP-IP5 (IP7), respectively (187)], led to
increased transcription and altered DNA methylation of mINO1. This resulted in
increased levels of mIno1 protein and increased intracellular inositol. Thus, in contrast
to positive regulation of INO1 in yeast, inositol pyrophosphate negatively regulates
mINO1 transcription. Intriguingly, similar to the yeast transcriptional repressor Opi1,
IP6K1 protein bound with high affinity to PA. Deletion of the PA-binding sequence
abrogated both nuclear localization of IP6K1 and repression of mINO1 transcription.
Our findings suggest a model whereby inositol pyrophosphate negatively regulates
inositol synthesis by PA-facilitated entry into the nucleus and repression of mINO1
transcription.
MATERIALS AND METHODS
Cell lines, yeast strains, and growth conditions
Wild type, IP6K1-KO, IP6K1-KO +pMX-IP6K1 and IP6K1-KO +pMX-EV MEF cell
lines (kindly provided by Dr. Anutosh Chakraborty, Scripps Research Institute), were
grown in DMEM (Gibco) containing 10% FBS (Hyclone) and penicillin (100 units/m)/
streptomycin (100 μg/ml) (Invitrogen) (188). IP6K1-KO +pMX-IP6K1 and IP6K1-KO
+pMX-EV cells were grown in this media supplemented with 4μg/ml blasticidin (Sigma).
The yeast S. cerevisiae kcs1∆ strain was obtained from Yeast Deletion Clones
(Invitrogen). Yeast cells were grown at 30°C or 37°C in synthetic complete (SC) medium,
which contained glucose (2% w/v) and necessary supplements including adenine (20
mg/liter), arginine (20 mg/liter), histidine (20 mg/liter), methionine (20 mg/liter),
tryptophan (20 mg/liter), leucine (60 mg/liter), lysine (200 mg/liter), threonine (300
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mg/liter), ammonium sulfate (0.2% w/v), inositol-free Difco vitamin mix, vitamin-free
yeast base, plus agar (2% w/v) for solid medium. Inositol (75 μM) was added separately
as indicated.
Real-time PCR
MEF cells were grown in DMEM containing 10% FBS. RNA was extracted from
cells by using RNeasy plus Mini Kit (QIAGEN), and was converted to cDNA with a
Transcriptor First Strand cDNA Synthesis Kit (Roche). RT-PCR was performed using
Brilliant III Ultra-Fast SYBR green qPCR master mix (Agilent) and MX3000p qPCR
System (Agilent). mRNA levels were normalized to GAPDH.
Immunoblotting
Cells were harvested, washed with ice-cold PBS and lysed by vortexing in lysis buffer
(50 mM Tris-HCL, 125 mM NaCl, 1% NP40, 2 mM EDTA and 1X protease inhibitor) for
30 min at 4°C. Protein concentration was determined using a Pierce BCA Protein Assay
Kit (Thermo). Cell extract corresponding to 30 μg protein was analyzed by SDS-PAGE
on a 10% gel. Immunoblotting was performed using primary antibodies against mIno1
(ISYNA1) (sc-134687, rabbit, Santa Cruz), IP6K1 (GTX103949, rabbit, Gene Tex), βactin (sc-69879, mouse, Santa Cruz) and corresponding secondary antibodies.
Measurement of intracellular inositol and G-6-P levels in MEF cells
Intracellular inositol levels were determined as described before using the
method of Maslanski and Busa (174). In brief, MEF cells were lysed in lysis buffer (50
mM Tris-HCL, 125mM NaCl2, 1% NP40 and 2mM EDTA) at 4°C. Cell extracts were
mixed with 7.5% perchloric acid and centrifuged at 10,000 g for 10 min at 4°C.
Supernatants were collected and titrated with ice cold KOH to pH 7. Samples were
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clarified by centrifugation and loaded onto columns containing 1 ml AG 1-X8 resin/H20
(1:1) mixture. Inositol was eluted with 5 ml dH2O, eluates were dried in an oven at 70°C
and stored at -80°C. Prior to assay, samples were dissolved in dH2O. Inositol content in
samples was measured as described previously (62).
To determine intracellular G-6-P levels, MEF cells were washed twice with ice
cold PBS. Cell pellets were mixed with 1 ml ice cold MeOH:CHCL 3 (2:1), vortexed and
stored at -20°C for 2 h. Samples were then mixed with extraction solution (50% MeOH,
4 mM tricine pH 5.4) and centrifuged at 18,000 g for 10 min. The upper phase was
collected and kept on ice. The lower chloroform phase was extracted again with
extraction solution. Upper phases from both extractions were combined, dried with a
speedvac, and stored at -80°C. Prior to assay, samples were dissolved in dH2O. G-6-P
content in samples was measured by the enzyme-coupled fluorescence assay
developed by Zhu et al. with modification (175).
Protein lipid overlay assay
pGEX-6P-2 plasmids harboring IP6K1 variants were constructed using a Q5 SiteDirected Mutagenesis Kit (NEB) with pGEX-6P-2-IP6K1 (from Dr. Anutosh Chakraborty)
as template. pGEX-6P-2-IP6K1 and corresponding mutants were transformed into BL21
(DE3) pLysS cells for IPTG-induced overexpression. E. coli cells were lysed by French
press to obtain cell extracts. IP6K1 proteins were then purified from E.coli cell extracts
using a GST spin purification kit (Life Technology). A protein lipid overlay assay was
performed according to the protocol of Dowler and co-workers with modification (189).
In brief, lyophilized lipids were dissolved in a 1:1 solution of methanol and chloroform to
make 1 mM stocks. Lipids were diluted to concentrations ranging from 500 to 5 μM in a
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2:1:0.8 solution of methanol:chloroform:water. Then 1 μl lipid samples from each dilution
were spotted on nitrocellulose membranes. After drying for 1 h at room temperature,
membranes were incubated in blocking buffer (50 mM Tris-HCL pH 7.5, 150 mM NaCl2,
0.1% Tween 20 and 2 mg/ml BSA) with gentle rocking for 1 h at room temperature.
Membranes were incubated overnight at 4°C with gentle rocking in 10 ml blocking buffer
containing 25 μg purified IP6K1 proteins. IP6K1 proteins bound to lipid drops on the
membrane were detected by immunoblotting using primary antibodies against IP6K1
(GTX103949, rabbit, Gene Tex) and corresponding secondary antibodies.
Fluorescence microscopy
pEGFP-C1 plasmids harboring IP6K1 variants were constructed using a Q5 SiteDirected Mutagenesis Kit (NEB) with pEGFP-C1-IP6K1 (from Dr. Anutosh Chakraborty)
as template. IP6K1-KO cells were transfected with pEGFP-C1-IP6K1 plasmid and
corresponding mutants using Lipofectamine 2000 (Life technology). Fluorescence
microscopy was performed using an Olympus BX41 fluorescence microscope. Images
were acquired using an Olympus Q-Color3 camera operated by QCapture2 software. All
pictures were taken at 400X at room temperature.
Determination of DNA methylation levels
Genomic DNA samples extracted from WT and IP6K1-KO cells using a Wizard
Genomic DNA Purification Kit (Promega) were subjected to DNA bisulfite conversion
using an EZ DNA Methylation-Gold Kit (Zymo Research), and sequencing for the
determination of methylation levels.
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Table 3-1. RT-PCR primers used in this study
________________________________________________________
Gene

Sequence

mINO1 (Isyna1)

CCTGTAGTGAATGCCCTCTTC
CGCTCCATCTTGTGCTCTAATA

Gapdh1

AACAGCAACTCCCACTCTTC
CCTGTTGCTGTAGCCGTATT
________________________________________________________
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RESULTS
IP6K1 rescues inositol deficiency in the yeast kcs1Δ mutant
We have previously shown that Kcs1-catalyzed inositol pyrophosphate synthesis
is required for optimal transcription of INO1 in yeast (167). To determine if mouse IP6K1
can supply the function of yeast Kcs1, we expressed IP6K1 in the yeast kcs1∆ mutant.
As seen in Fig. 3-1, kcs1∆ mutant cells expressing the wild type IP6K1 gene grew
normally, while the kinase-dead IP6K1 (IP6K1KD) gene (28) failed to support growth of
the kcs1∆ mutant. Therefore, mouse IP6K1 is the functional homolog of yeast Kcs1,
which can rescue defective inositol synthesis in yeast by restoring inositol
pyrophosphate synthesis.
IP6K1 is a negative regulator of inositol synthesis in MEF cells
To ascertain if IP6K1 regulates mammalian inositol synthesis, we determined the
effects of knocking out IP6K1 (IP6K1-KO). Surprisingly, IP6K1-KO cells exhibited a 5fold increase in mINO1 mRNA levels (Fig. 3-2A). Consistent with increased transcription,
mIno1 protein levels were also increased in IP6K1-KO cells (Fig. 3-2B), and inositol
levels were 75% higher in the IP6K1-KO cells than in WT cells (Fig. 3-2C). Levels of
intracellular G-6-P, the substrate for inositol synthesis, decreased correspondingly (Fig.
3-2D). Taken together, these findings indicate that IP6K1 is a negative regulator of
inositol synthesis.
IP6K1 regulates mINO1 DNA methylation
As seen in Fig. 3-2B, two mIno1 proteins were expressed in IP6K1-KO cells. A
previous study reported that alternative splicing of mINO1 results in α, β, and γ mRNA
transcripts, which generate protein isoforms (190). The α transcript is the full-length
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Figure 3-1. IP6K1 rescues kcs1∆ inositol auxotrophy. Serial dilutions of yeast kcs1∆
cells transformed with indicated plasmids were spotted on synthetic complete Ura medium in the presence or absence of 75 μM inositol. Plates were incubated at the
indicated temperatures for 3 days.
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Figure 3-2. Inositol synthesis is up-regulated in IP6K1-KO cells. A, mINO1 mRNA
levels are increased in IP6K1-KO cells. mINO1 mRNA levels were determined by RTPCR (n=4) (*p<0.05). B, mIno1 protein levels were profoundly increased in IP6K1-KO
cells (left). The expression of IP6K1 in IP6K1-KO cells restored mIno1α and mIno1γ
levels (right). 30 μg total cell extract from each sample were subjected to Western blot
analysis using 10% SDS-PAGE gel. C, IP6K1-KO cells exhibited increased intracellular
inositol levels. Intracellular inositol levels in MEF cells were determined as described in
“Experimental procedures” (n=6) (*p<0.05). D, Intracellular G6P levels were decreased
in IP6K1-KO cells. Intracellular G6P levels in MEF cells were determined by enzymecoupled fluorescence assay as described in “Experimental procedures” (n=6) (*p<0.05).
Values are mean ± SEM. Statistical significance was determined by unpaired t test.
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mRNA, the β mRNA contains a truncated exon 2, and the γ mRNA is transcribed from a
second ATG site within the unremoved intron 4. To determine which isoforms are
expressed in IP6K1-KO cells, we compared cDNA from WT and IP6K1-KO cells by
PCR analysis, using specific primers that distinguished among these mRNAs. Both the
α and γ mRNAs were present in the IP6K1-KO cells, but only the α mRNA was detected
in WT cells (data not shown). These findings indicated that isoforms observed in Fig. 32B are translated from the α (upper band) and γ (lower band) splicing forms.
Previous studies indicated that in vitro methylation of the human INO1 promoter
significantly decreased reporter gene expression (191). To determine if altered DNA
methylation could account for the mIno1 isoforms observed in IP6KO cells, we analyzed
methylation of mINO1 DNA using DNA bisulfite conversion of WT and IP6K1-KO
genomic DNA followed by probing with primers targeting the sequence from – 286 to
+160, which is enriched in CpG islands (Fig. 3-3). In the mINO1 promoter region, most
of the CpG sites exhibited a similar, but slightly decreased, pattern of methylation in
IP6K1-KO cells compared to WT cells. However, the CpG sites between the first and
second ATGs exhibited markedly less methylation in IP6K1-KO cells. These findings
suggest that IP6K1 may negatively regulate mINO1 transcription by increasing the
methylation of mINO1 DNA.
IP6K1 requires PA-binding for nuclear localization and repression of mINO1
transcription
As discussed above, negative regulation of INO1 transcription in yeast is
mediated by the Opi1 transcriptional repressor. While homologs of Opi1 have not been
identified in mammalian cells, we considered the possibility that IP6K1 may exhibit
functional similarity to Opi1. Opi1 is retained in the cytoplasm by binding to PA, and
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Figure 3-3. Methylation pattern of mINO1 DNA is altered in IP6K1-KO cells. A, DNA
methylation levels in MEF cells were determined as described in “Experimental
procedures”. CpG islands are depicted as balloons. Methylated cytosines are filled, and
unmethylated cytosines are unfilled. B, Raw data of mINO1 DNA methylation
experiment. CpG islands are depicted in bold. Methylated cytosines are depicted in red,
whereas unmethylated cytosines are depicted in black. CpG islands with altered
methylation in IP6K1-KO cells are highlighted with yellow shade, and the start codon is
highlighted with green shade.
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translocates to the nucleus when PA is limiting. As shown in the protein lipid overlay
assay (Fig. 3-4A), purified recombinant IP6K1 displayed a markedly high affinity to PA,
and only weak binding to other phospholipids.
To determine the functional significance of PA-binding, we constructed the IP6K1
deletions shown in Fig. 3-5 and determined the ability of truncated proteins to bind PA.
Deletion of Q2 but not the other sequences greatly diminished PA-binding activity of
IP6K1 (Fig. 3-4B). The Q2 domain alone was sufficient for PA-binding (Fig. 3-4D). We
then determined the effect of Q2 deletion on localization of IP6K1. IP6K1-KO cells
expressing GFP-tagged wild type IP6K1 exhibited intense fluorescence in the nucleus in
about 75% of cells (Fig. 3-6). Deletion of the Q2 domain resulted in decreased nuclear
localization in more than 60% of cells. Interestingly, IP6K1-KO cells expressing GFPQ2∆ exhibited increased mINO1 mRNA levels compared to cells expressing wild type
IP6K1 (Fig. 3-7). These results indicate that interaction with PA facilitates IP6K1 nuclear
localization and is required by IP6K1 to repress mINO1 expression.
Protein BLAST sequence alignment identified a small region of sequence
homology between the Q3 domain of IP6K1 and yeast Opi1, especially in the region of
positively charged residues that are critical to the PA-binding activity of the yeast protein
(Fig. 3-5). The IP6K1 region containing these sequences was designated HOPA
(Homology to Opi1 PA-binding). To determine the function of the HOPA domain, we
constructed an IP6K1 mutant in which this region is deleted (HOPA∆). The HOPA∆
protein exhibited normal PA-binding activity (Fig. 3-4C) as expected, as PA-binding is
conferred by the Q2 domain. Strikingly, however, deletion of the HOPA domain resulted
in exclusion of IP6K1 from the nucleus in more than 70% of cells (Fig. 3-6). Consistent
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Figure 3-4. IP6K1 binds preferentially to phosphatidic acid (PA). A, IP6K1 protein
was purified from E. coli cells expressing the IP6K1 gene on the pGEX-6-P2
overexpression vector. Serial dilutions of the indicated lipids were spotted on a
nitrocellulose membrane, which was incubated overnight in buffer containing 25 μg of
IP6K1 protein. Interactions between IP6K1 and lipids were determined by
immunoblotting. B, Deletion of the Q2 domain of IP6K1 decreased binding to PA. C,
Deletion of the HOPA domain of IP6K1 did not affect binding to PA. D, Q2 domain of
IP6K1 binds to PA.
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Figure 3-5. IP6K1 exhibits sequence homology to yeast Opi1 (upper panel). The
IP6K1 HOPA domain that exhibits homology to the PA-binding domain of yeast Opi1 is
highlighted in red. The catalytic motif of IP6K1 is highlighted in blue. The PA-binding
domain of yeast Opi1 is highlighted in gray. The nuclear localization signal (NLS) of
yeast Opi1 is underlined in purple. IP6K1 deletion mutants were constructed by sitedirected mutagenesis according to the schematic figure (lower panel). Residues deleted
are indicated by numbers above the bar.

58

Figure 3-6. PA-binding is required for nuclear localization of IP6K1. IP6K1-KO cells
were transfected with plasmids harboring GFP-tagged WT or mutant IP6K1. Intracellular
localization of IP6K1 (upper panel) was determined by fluorescence microscopy. The
number of cells showing each phenotype (lower panel) was determined in three
independent experiments (n > 150). Values are mean ± SEM.
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Figure 3-7. PA-binding to IP6K1 is required for repression of mINO1 transcription.
IP6K1-KO cells were transfected with plasmids harboring the indicated GFP-tagged
IP6K1 mutants. The mINO1 mRNA levels were determined by RT-PCR (2 independent
experiments with 2 replicates) (*p<0.05). Values are mean ± SEM. Statistical
significance comparing transcription levels to KO+IP6K1 control was determined by
unpaired t test.
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with this finding, cNLS Mapper predicts a potential nuclear localization signal (NLS) in
the HOPA domain. Interestingly, the NLS of yeast Opi1 is in the homologous region (Fig.
3-5). Expression of HOPA∆ in IP6K1-KO cells resulted in increased mINO1 mRNA
levels relative to cells expressing WT IP6K1 (Fig. 3-7). The catalytic motif of IP6K1 also
lies in the Q3 domain (192,193). Expression of Q3∆, which lacks both the HOPA
domain and the catalytic motif, also led to increased mINO1 mRNA levels in IP6K1-KO
cells (Fig. 3-7).
The Q1∆ deletion did not affect nuclear localization (Fig. 3-6) or mINO1 mRNA
levels. Although the Q4∆ deletion did not affect nuclear localization (Fig. 3-6), it resulted
in increased mINO1 transcription (Fig. 3-7). The Q4 domain contains the ATP-binding
motif (192,193), which is critical for IP6K1 catalytic activity (28,194,195). Increased
mINO1 transcription in IP6K1-KO cells expressing Q4∆ indicates that IP6K1 requires
catalytic activity to suppress mINO1 expression. Together, these findings indicate that
binding of PA is required for localization of IP6K1 to the nucleus, where the ATP-binding
dependent synthesis of inositol pyrophosphate represses mINO1 transcription.
DISCUSSION
Despite the essential role of inositol in cell function, the mechanisms that
regulate inositol synthesis in mammalian cells have not been characterized. The current
study demonstrates for the first time that de novo synthesis of inositol in MEF cells is
regulated by inositol hexakisphosphate kinase 1 (IP6K1), which mediates transcriptional
control of the gene (mINO1) coding for the rate-limiting enzyme of inositol synthesis.
Our findings indicate that IP6K1 alters methylation and negatively regulates
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transcription of mINO1, and that binding of IP6K1 to PA is essential for nuclear
localization of IP6K1 and repression of transcription.
IP6K1-KO cells exhibited increased expression of mINO1 (Fig. 3-2A), which was
accompanied by increased mIno1 protein and inositol levels (Fig. 3-2B,C). These
findings indicate that IP6K1 is a negative regulator of mINO1 transcription. Increased
mINO1 expression in IP6K1-KO cells is most likely due to decreased DNA methylation
(Fig. 3-3), which is associated with silencing of gene expression (196). Seelan et al.
investigated the effects of methylation of the INO1 promoter on transcription of INO1 in
human neuroblastoma cells transfected with plasmids carrying in vitro methylated INO1
(191). They determined that the methylated INO1 promoter led to significantly less
transcription than the non-methylated control. Our finding that IP6K1-KO cells exhibited
both increased mINO1 transcription and decreased DNA methylation is the first in vivo
demonstration of regulation of mINO1 by in vivo methylation.
Two lines of evidence support a role for regulation of methylation by inositol
pyrophosphate. First, IP7 (the product of IP6K1) was shown to inhibit Akt (197), which
negatively regulates methylation of imprinted genes (198). Therefore, the deficiency of
IP7 in IP6K1-KO cells may lead to decreased mINO1 methylation as a result of
increased Akt signaling. Second, IP6K1 associates with chromatin and controls histone
demethylation by regulating the demethylase Jumonji domain-containing 2C (JMJD2C),
which catalyzes the removal of trimethyl groups from lysines 9 and 36 of histone H3
(26). IP6K1-KO cells exhibited decreased levels of histone H3 lysine 9 trimethylation
(H3K9me3) and increased transcription of JMJD2C-regulated genes. Interestingly, DNA
regions associated with H3K9me3 exhibited increased methylation (199), while mutation
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of H3K3 led to decreased DNA methylation (200). In this light, IP6K1 may regulate
mINO1 methylation indirectly by regulating histone modification.
IP6K1 exhibits dual localization in the cytoplasm and nucleus (Fig. 3-6). The
probable NLS of IP6K1 was localized to the Q3 domain, the deletion of which led to
exclusion of IP6K1 from the nucleus (Fig. 3-6). Binding of the IP6K1 Q2 domain to PA
is essential for translocation of the protein to the nucleus and repression of mINO1
transcription (Figs. 3-6, 3-7). Binding to PA has been shown to promote nuclear
localization of transcription factor WER in Arabidopsis (201,202). Inhibition of
phospholipase D (PLD), resulting in decreased conversion of phosphatidylcholine
(PC) to PA, suppresses nuclear localization of WER (202). Nuclear association of PLD
has been reported both in mammals and plants (203,204). Furthermore, PA synthesis
has been demonstrated in the nuclear envelope of mammalian cells (205,206), and PA
has been detected in the nucleus (207). To our knowledge, the current study is the first
to report the dependence on binding to PA for nuclear localization of a mammalian
protein.
The catalytic function of IP6K1 is necessary for repression of mINO1
transcription, as deletion of the Q4 domain resulted in increased mINO1 expression (Fig.
3-7). The “SLL” ATP-binding motif, which is highly conserved in the inositol
polyphosphate kinase (IPK) family, is localized in the Q4 domain (192,193), and
mutation of the ATP-binding site impairs catalysis (28,194). Therefore, the synthesis of
inositol pyrophosphate is required for repression of mINO1 transcription.
Surprisingly, while Kcs1 and IP6K1 carry out the same enzymatic function, they
regulate INO1 expression in an opposite manner in yeast and mouse cells. INO1
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expression is positively regulated in yeast by Kcs1 (167) but negatively regulated by
IP6K1 in mouse cells (Fig. 3-2A). In fact, the observed negative regulation of mINO1
expression by IP6K1 more closely resembles that of the yeast transcriptional repressor
Opi1. Both Opi1 and IP6K1 bind to PA, translocate from the cytoplasm to the nucleus,
and repress INO1 transcription. However, while PA-binding retains Opi1 in the
cytoplasm, PA-binding mediates IP6K1 nuclear translocation (Fig. 3-6). In yeast, PA
levels indirectly reflect inositol synthesis, which regulates INO1 expression. As inositol
does not regulate INO1 expression in mammalian cells (9, 22), we speculate that PA
levels may reflect the state of cellular energy metabolism, which would affect inositol
synthesis as a result of competition for the common substrate G-6-P.
Inositol pyrophosphate regulation is an intriguing area of signaling research.
Shears suggested that inositol pyrophosphates are metabolic messengers that respond
to the cellular energy demand (208). In support of this concept, perturbing the energy
balance in mammalian cells leads to decreased synthesis of inositol pyrophosphates
(209). Interestingly, inositol pyrophosphate deficiency in yeast kcs1∆ cells leads to
dysfunctional mitochondria with greatly reduced respiratory capacity (210). To
compensate, glycolysis is increased to generate ATP. G-6-P is the branch point of
inositol de novo synthesis and glycolysis. We observed decreased intracellular G-6-P
levels in IP6K1-KO cells (Fig. 3-2D), which may be caused, at least in part, by increased
inositol synthesis. Therefore, IP6K1 may repress mINO1 expression to maintain inositol
synthesis at a relatively low level, reserving G-6-P for glycolysis.
Our findings suggest the following model (Fig. 3-8). Translocation of IP6K1 to the
nucleus is facilitated by interaction with PA. In the nucleus, IP6K1 associates with
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chromatin and synthesizes IP7/PP-IP4. IP7/PP-IP4 inhibits transcription of mINO1 by
increasing methylation of mINO1 DNA, inhibiting the recruitment of transcription factors
to the promoter region of mINO1, or perturbing assembly of the transcription complex.
This study is the first to describe the molecular control of de novo synthesis of inositol in
mammalian cells, and suggests that inositol synthesis and cellular energy demand are
coordinately controlled. These findings have important implications for understanding
essential cellular functions that are dependent on inositol, and human disorders that
result from perturbation of inositol homeostasis.
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Figure 3-8. Model of regulation of mINO1 transcription by IP6K1. PA-binding
facilitates localization of IP6K1 to the nucleus, where it associates with chromatin and
synthesizes IP7/PP-IP4. IP7/PP-IP4 represses mINO1 expression by promoting
methylation of mINO1 DNA and/or inhibiting the transcription apparatus.

66

CHAPTER 4 VPA INHIBITS EXPRESSION OF HEXOSE TRANSPORTER GENES
HXT2 AND HXT4 VIA TRANSCRIPTION REPRESSOR MIG1
INTRODUCTION
VPA has been used for decades for the treatment of bipolar disorder. However,
the therapeutic mechanism underlying this drug is not well understood, which hinders
the development of novel anti-bipolar drugs with improved efficacy. Among many
biochemical outcomes of VPA treatment, VPA-induced inositol depletion has been
proposed as one potential mechanism (31). In Saccharomyces cerevisiae cells, VPA
depletes intracellular inositol by inhibiting myo-inositol-3-phosphate synthase (MIPS)
(59,60,64), which catalyzes the rate-limiting step of inositol de novo synthesis (810,169,170). In addition, VPA was shown to upregulate expression of glycolysis genes
in yeast (unpublished data of Shyamala Jadhav). Interestingly, MIPS activity is greatly
inhibited by the glycolysis intermediate dihydroxyacetone phosphate (DHAP) (178,179).
Yeast mutants that accumulate intracellular DHAP are inositol auxotrophs (178). These
findings suggest that inositol de novo synthesis and glycolysis are intrinsically
coordinated. As both glycolysis and inositol synthesis pathways utilize glucose 6phosphate (G-6-P) as the common substrate, VPA-induced perturbation of glycolysis
and inositol synthesis may both result from changes in G-6-P metabolism.
Glucose is the preferred carbon source for most eukaryotic cells. To adapt to
fluctuation of glucose in the environment, yeast cells developed mechanisms to sense
and respond to glucose availability. The first step in the regulation of glucose
metabolism is glucose uptake, which is regulated by the transcription of hexose
transporter (HXT) genes (211). Twenty genes that encode proteins in the hexose
transporter family have been identified, including HXT1-HXT17 , SNF3, RGT2, and
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GAL2 (212). Snf3 and Rgt2 are glucose sensors, which regulate the expression of HXT
genes but do not transport glucose (213,214). Only HXT1-HXT7 are known to express
functional hexose transporters (215). HXT1 and HXT3 encode low-affinity glucose
transporters (212,216). Their expression is induced by high levels of glucose (217).
HXT2, HXT6, and HXT7 encode high-affinity transporters, while HXT4 encodes
intermediate-affinity transporter (216). Transcription of HXT2 and HXT4 is induced by
low levels of glucose (218) and repressed by high levels of glucose (217,219-221).
HXT6 and HXT7 transcription is also repressed in high glucose (222).
The repression of HXT2 and HXT4 under high glucose conditions is mediated by
the Snf1-Mig1 pathway (211,223,224). Mig1 is a zinc-finger protein that binds to DNA
and recruits co-repressors Ssn6 and Tup1 to repress gene expression (225). Snf1, the
yeast homolog of mammalian AMP-activated kinase, is activated under low glucose
conditions. Active Snf1 phosphorylates Mig1 on multiple serine residues (226-228).
Phosphorylated Mig1 translocates from the nucleus to the cytoplasm to allow
expression of glucose-repressible genes, including HXT2 and HXT4 (229). In high
glucose, both Mig1 and Snf1 are dephosphorylated by the Reg1-Gly7 protein
phosphatase complex, which allows Mig1 to enter the nucleus and restore glucose
repression (230,231).
In this study, I discovered that VPA decreased expression of hexose transporter
genes and induced Mig1 nuclear translocation. VPA treated cells exhibited decreased
expression of HXT2, HXT4, HXT6, and HXT7. The ablation of MIG1 or REG1 alleviated
VPA-induced inhibition of HXT2 and HXT4 expression. Furthermore, VPA triggered
Mig1 nuclear translocation under non-repressive conditions. This study shows for the
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first time that VPA inhibits expression of hexose transporter genes via Mig1. Decreased
expression of hexose transporter genes may account for VPA-induced G-6-P depletion.
MATERIALS AND METHODS
Yeast strains
All strains used in this study were in the W303 background. mig1△ and reg1△
strains were constructed by gene knockout using KanMX and ble (phleomycin
resistance gene) cassettes, respectively. The MIG1-GFP:KanMX NRD1-RFP:HghMX
strain was kindly provided by Dr. Stefan Hohmann from University of Gothenburg,
Sweden (232).
Growth media
Yeast cells were grown at 30°C in synthetic complete (SC) medium, which
contained glucose (2% w/v) and necessary supplements including adenine (20 mg/liter),
arginine (20 mg/liter), histidine (20 mg/liter), methionine (20 mg/liter), tryptophan (20
mg/liter), leucine (60 mg/liter), lysine (200 mg/liter), threonine (300 mg/liter), ammonium
sulfate (0.2% w/v), inositol-free Difco vitamin mix, and vitamin-free yeast base. VPA (1
mM) was added separately as indicated.
Hexokinase activity assay
WT cells were grown in SC medium to the mid log phase and treated with 1 mM
VPA for 3 h. Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 6 mM MgCl2) by
vortexing with acid-washed glass beads at 4°C in the presence of 1X protease inhibitor
and 1X phosphatase inhibitor. Cell extract was mixed with reaction buffer (20 mM TrisHCl pH 7.5, 6 mM MgCl2, 1 mM ATP, 0.5 mM NAD+ and 2 mM glucose). Reactions
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were started by adding 1unit/ml glucose-6-phosphate dehydrogenase. Reaction rates
were determined by monitoring NADH production at 340 nM in 15 min (233).
Pyruvate kinase assay
WT cells were grown in SC medium to the mid log phase and treated with 1 mM
VPA for 3 h, then lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 6 mM MgCl2) by
vortexing with acid-washed glass beads at 4°C in the presence of 1X protease inhibitor
and 1X phosphatase inhibitor. Cell extract was mixed with reaction buffer (20 mM TrisHCl pH 7.5, 6 mM MgCl2, 1 mM ADP, 0.4 mM NADH, 1 unit/mL lactate dehydrogenase
and 1 mM phosphoenolpyruvate). Reaction rates were determined by monitoring NADH
consumption at 340 nM for 15 min (233).
Measurement of intracellular G-6-P levels
To determine intracellular G-6-P levels, yeast cells were washed twice with icecold dH2O, and lysed in dH2O containing 1X protease inhibitor by vortexing with acidwashed glass beads at 4°C. Cell extracts were mixed with 1 ml ice cold MeOH:CHCL3
(2:1), vortexed and stored at -20°C for 2 h. Samples were then mixed with extraction
solution (50% MeOH, 4 mM tricine pH 5.4) and centrifuged at 18,000 g for 10 min. The
upper phase was collected and kept on ice. The lower chloroform phase was extracted
again with extraction solution. Upper phases from both extractions were combined,
dried with a speedvac, and stored at -80°C. Prior to assay, samples were dissolved in
dH2O. G-6-P content in samples was measured by the enzyme-coupled fluorescence
assay developed by Zhu et al. with modification (175).
Real-time PCR
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Yeast mRNA was extracted from cells using the RNeasy plus Mini Kit (QIAGEN),
and was converted to cDNA with a Transcriptor First Strand cDNA Synthesis Kit
(Roche). RT-PCR was performed using Brilliant III Ultra-Fast SYBR green qPCR master
mix (Agilent) and MX3000p qPCR System (Agilent). mRNA levels were normalized to
TCM1 or ALG9 as indicated.
Fluorescence microscopy
MIG1-GFP:KanMX NRD1-RFP:HghMX cells were grown in SC medium to the
early stationary phase, and treated with 1 mM VPA. Fluorescence microscopy was
performed using an Olympus BX41 fluorescence microscope. Images were acquired
using an Olympus Q-Color3 camera operated by QCapture2 software. All pictures were
taken at 400X at room temperature.
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Table 4-1. Strains used in this study.
Strain

Genotype

Source

W303

MATa his3, leu2, ura3, trp1, ade2

Andoh T. (173)

mig1∆

MATa his3, leu2, ura3, trp1, ade2, mig1::KanMX

This study

reg1∆

MATa his3, leu2, ura3, trp1, ade2, reg1::ble

This study

MIG1-GFP NRD1-RFP MATa his3, leu2, ura3, trp1, ade2,

Hohmann S. (232)
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Table 4-2. RT-PCR primers used in this study.
________________________________________________________
Gene

Sequence

HXT1

TGTCGGTGGTATCACAGTTT
CAAGGTGCCTCTCATTTCAC

HXT2

GTGTCTATTGGGTGGTTCTG
GCCTTGGAAGATGGTTGAT

HXT3

CCCAGACCATCCATTCATTC
GGCTTACCAGTGAACAACTC

HXT4

GGCTGTTTGGTCTTTTCTTAC
AGCGTTGTAGTCAGTACCT

HXT6

CTTTGGAAGAAGTCAACACC
CTTATCATCGTGAGCCATTTC

HXT7

CTTTGGAAGAAGTCAACACC
CTTGTCATCGTGAGTCATTTC

HXK1

TACCTCCTACCCAGCAAGAA
AGAGTGGTCTTGACACCAAAG

HXK2

CTGTGAATACGGTTCCTTCG
GTTTGTTGGCCTGGTCTT

GLK1

CTCAAGCACTTGCCTACTAC
CAAGAACATCCCTGAGACAC

TCM1

CCACGTCACGGTCATTTAG
GTCATACCAGCCTTGTAACC

ALG9

TGGTCTTCTTCCAGGTGAT
GGGCGACGATGTCAATAAA
________________________________________________________
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RESULTS
Chronic VPA treatment decreases intracellular G-6-P levels
A microarray analysis carried out by my lab member, Shyamala Jadhav, revealed
upregulation of glycolysis genes after chronic treatment with VPA, suggesting that VPA
impacts energy metabolism. I conducted a time course study of intracellular G-6-P
levels in cells exposed to VPA. As seen in Fig. 4-1, after an initial increase at 30 min, G6-P levels decreased with chronic exposure to VPA. Hexokinases catalyze the
synthesis of G-6-P from glucose (234). VPA did not inhibit hexokinases activities in vitro
(Fig. 4-2), suggesting that VPA does not inhibit G-6-P synthesis. Pyruvate kinase
catalyzes the irreversible conversion of phosphoenolpyruvate to pyruvate, which is one
of the rate-limiting and final step of glycolysis (234). Pyruvate kinase activity was not
affected by VPA (Fig. 4-2). As activities of enzymes involved in G-6-P synthesis and
glycolysis are not affected by VPA, the intracellular G-6-P depletion may result from
decreased glucose uptake.
VPA decreases expression of hexose transporter genes
I determined effects of VPA on expression of hexose transporter genes .
Surprisingly, VPA treatment resulted in significantly decreased mRNA levels of HXT2,
HXT4, HXT6, and HXT7 (Fig. 4-3). The expression of HXT1 and HXT3, which encode
low affinity glucose transporters, was not affected by VPA (data not shown). VPA has
been reported to be inhibitor of histone deacetylase (HDAC), which regulates gene
expression by deacetylating histones. To determine if changes in transporter gene

74

Figure 4-1. VPA depletes intracellular glucose 6-phosphate levels. Cells were
grown in SC medium to the early log phase and treated with 1 mM VPA. Intracellular
inositol levels were determined as described in “Materials and Methods”. Data shown
are representative of three independent experiments. Values shown are mean ± SEM.
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Figure 4-2. VPA does not affect hexokinase (HK) and pyruvate kinase (PK)
activities in vitro. Yeast cells were grown in SC medium to the early log phase and
treated with 1 mM VPA. HK and PK activities were determined as described in
“Materials and Methods”. Values shown are mean ± SEM. Date shown are
representative of three independent HK assays and two independent PK assays.
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Figure 4-3. VPA inhibits expression of HXT2, HXT4, HXT6, and HXT7. Yeast cells
were grown in SC medium to the early log phase and treated with 1 mM VPA. mRNA
levels of hexose transporter genes were determined by RT-PCR.
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expression result from HDAC inhibition, we determined mRNA levels of HXT2 and
HXT4 in yeast cells treated with TSA, a potent HDAC inhibitor. As seen in Fig. 4-4, TSA
treatment did not inhibit HXT2 and HXT4 expression, suggesting that VPA did not affect
HXT2 and HXT4 expression by HDAC inhibition.
VPA-induced decrease in hexose transporter gene expression is Mig1 dependent
The expression of HXT2 and HXT4 is repressed by Mig1 (211,223,224). The
ablation of MIG1 delayed the inhibition of HXT2 and HXT4 expression in VPA-treated
cells (Fig. 4-5), suggesting that Mig1 mediated the effect of VPA on expression of
hexose transporter genes. The intracellular localization of Mig1 is determined by its
phosphorylation status. Under high glucose conditions, Mig1 is dephosphorylated by the
Reg1-Glc7 complex, which leads to Mig1 nuclear translocation to repress HXT2 and
HXT4 expression (225,230). Under glucose-limited conditions, Mig1 is phosphorylated
by Snf1, and therefore excluded from the nucleus to allow expression of HXT2 and
HXT4 (226). We determined the effect of VPA on Mig1 nucleocytoplasmic distribution in
MIG1-GFP:KanMX NRD1-RFP:HghMX cells, which express GFP-tagged Mig1 and
RFP-tagged nuclear protein Nrd1 (232). Surprisingly, VPA triggered Mig1 nuclear
translocation at the early stationary phase (Fig. 4-6), when glucose was depleted in the
media. Mig1 nuclear translocation persisted for up to 3 h after VPA treatment. These
findings suggest that VPA inhibits HXT2 and HXT4 expression by promoting Mig1
mediated transcription repression.
VPA-induced repression of hexose transporter gene expression is Mig1
dependent
As discussed above, Mig1 dephosphorylation by the Reg1-Glc7 complex is
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Figure 4-4. Histone deacetylase inhibition does not inhibit HXT2 or HXT4
expression. Cells were grown in SC medium to the early log phase and treated with 2
μM or 10 μM TSA. mRNA levels of hexose transporter genes were determined by RTPCR.
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Figure 4-5. VPA-induced inhibition of HXT2 and HXT4 expression is delayed in
mig1∆ cells. WT and mig1∆ cells were grown in SC medium to the early log phase and
treated with 1 mM VPA. mRNA levels of hexose transporter genes were determined by
RT-PCR.
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Figure 4-6. VPA triggers Mig1 nuclear translocation under low glucose conditions.
MIG1-GFP:KanMX NRD1-RFP:HghMX cells were grown in SC medium to the early
stationary phase and treated with 1 mM VPA. Mig1 intracellular localization was
determined by fluorescence microscopy.

81

required for Mig1 entry into the nucleus under high glucose conditions. We determined
HXT2 and HXT4 mRNA1 levels in VPA treated reg1∆ cells. VPA did not inhibit HXT4
expression in reg1∆ cells (Fig. 4-7). However, deletion of REG1 did not restore HXT2
mRNA levels in VPA-treated cells (data not shown), which suggested that Mig1 may
require additional co-factors to repress HXT2 expression. These findings support the
hypothesis that VPA promotes Mig1 dephosphorylation via the Reg1-Gly7 complex to
repress expression of hexose transporter genes, and thereby reduces intracellular G-6P levels.
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Figure 4-7. Reg1 is required for VPA-induced inhibition of HXT4 expression. reg1∆
cells were grown in SC medium to the early log phase and treated with 1 mM VPA.
mRNA levels of HXT4 were determined by RT-PCR.
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DISCUSSION
The current study demonstrates for the first time that VPA depletes intracellular
G-6-P levels. Furthermore, VPA promotes Mig1 mediated transcription repression of
hexose transporter genes, possibly by activating the Reg1-Glc7 protein phosphatase
complex. G-6-P plays a central role in energy metabolism. These findings suggest that
VPA-induced cellular effects, including inositol depletion, increased glycolytic gene
expression, and increased ethanol production, may result, at least partially, from
perturbation of G-6-P metabolism.
Chronic VPA treatment depleted intracellular G-6-P levels (Fig. 4-1). G-6-P is at
the branch point of glycolysis, the inositol de novo synthesis pathway, the pentose
phosphate pathway, and the glycogen synthesis pathway. Therefore, perturbation of G6-P metabolism is expected to affect these pathways. Glycolysis and inositol synthesis
both utilize G-6-P as a substrate. Interestingly, the Km of MIPS for G-6-P (1.18 mM) is
much higher than that of the glycolytic enzyme phosphoglucoisomerase (0.3 mM),
which convert G-6-P to fructose 6-phosphate (235,236). These findings suggest that G6-P depletion would drive G-6-P flux to glycolysis rather than to inositol synthesis.
Consistent with this hypothesis, VPA decreases inositol synthesis (60), upregulates
expression

of

glycolytic

genes,

and

increases

ethanol

production

(personal

communication with Shyamala Jadhav and Michael Salsaa). In this light, G-6-P
depletion may contribute, at least in part, to VPA-induced inositol depletion.
VPA decreased mRNA levels of HXT2, HXT4, HXT6, and HXT7 (Fig. 4-3), which
encode intermediate-affinity and high-affinity glucose transporters that function optimally
at glucose concentrations of 1% or lower (211). Decreased expression of HXT2 in VPA
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treated yeast cells was also observed in a microarray study carried out by my lab
member Shyamala Jadhav. The expression of HXT2, HXT4, HXT6, and HXT7 genes is
regulated in response to extracellular glucose concentrations (211). Low glucose (0.1%)
induces the expression of HXT2 and HXT4, while high glucose (4%) represses
expression of all four genes. The medium used in this study contains 2% glucose. As
glucose is gradually consumed, the expression of intermediate-affinity and high-affinity
glucose transporters is required by yeast cells to take up glucose efficiently. VPAinduced inhibition of HXT2, HXT4, HXT6, and HXT7 may decrease glucose uptake and
therefore deplete intracellular G-6-P.
Expression of HXT2 and HXT4 genes is repressed by the Mig1 repressor under
high glucose conditions (211). Deletion of the MIG1 gene delayed inhibition of HXT2
and HXT4 expression after VPA treatment (Fig. 4-5), suggesting that VPA inhibits
expression of HXT2 and HXT4 via Mig1. The yeast genome contains a MIG1 homolog,
MIG2, which has similar but not identical functions in regulating expression of glucose
repressible genes (225,237). Therefore, Mig2 may repress transcription of HXT genes
in response to VPA in mig1∆ cells at a slower rate.
Mig1 exhibits dual intracellular localization. Under low glucose conditions, Mig1 is
phosphorylated by Snf1 and localizes in the cytosol (226). In high glucose, Mig1 is
dephosphorylated by the Reg1-Gly7 protein phosphatase complex, which allows Mig1
to enter the nucleus and repress gene expression (225,230). Interestingly, VPA
triggered Mig1 nuclear localization under low glucose conditions (Fig. 4-6), which was
consistent with VPA-induced inhibition of HXT2 and HXT4 expression. These findings
suggest that VPA causes Mig1 dephosphorylation and thereby promotes its
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nucleocytoplasmic distribution. Deletion of the REG1 gene abolished the inhibitory
effect of VPA on HXT4 expression (Fig. 4-7), suggesting that VPA promotes Reg1-Gly7
mediated dephosphorylation of Mig1. In support of this hypothesis, my previous studies
have shown that VPA inhibits HXK1 and GLK1 expression in 30 min (Fig. 4-8).
HXK1, HXK2 and GLK1 encode glucose kinases that convert glucose to G-6-P (238). In
addition, Hxk2 functions as a transcription regulator, which represses expression of
HXK1 and GLK1 in response to availability of glucose (239). Similar to Mig1, Hxk2
shuttles in and out of the nucleus to regulate gene expression (240). Therefore, the
decrease in HXK1 and GLK1 mRNA levels in VPA treated cells suggests that VPA
triggers nuclear translocation of Hxk2. The nucleocytoplasmic distribution of Hxk2 is
determined by the phosphorylation status of the protein. The dephosphorylated Hxk2 is
imported into the nucleus, while the phosphorylated form is exported from the nucleus
to the cytoplasm (241). Interestingly, the phosphorylation and dephosphorylation of
Hxk2 are also carried out by Snf1 kinase and the Reg1-Glc7 protein phosphatase
complex (241). These findings suggest that VPA-induced inhibition of HXK1 and GLK1
expression may also result from Reg1-Glc7 mediated Hxk2 dephosphorylation.
My

study

suggests

the

following

model

(Fig.

4-9).

VPA

promotes

dephosphorylation of Mig1 via the Reg1-Glc7 complex, and triggers the nuclear
translocation of Mig1. In the nucleus, Mig1 represses expression of hexose transporter
genes, which leads to decreased glucose uptake. With limited availability of glucose, the
synthesis of G-6-P decreases accordingly and results in G-6-P depletion.
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Figure 4-8. VPA decreases HXK1 and GLK1 expression in 30 min. WT cells were
grown in SC media to the early log phase and treated with 1 mM VPA. mRNA levels of
HXK1, HXK2 and GLK1 were determined by RT-PCR.
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Figure 4-9. Model of VPA-induced glucose 6-phosphate depletion. VPA leads to
dephosphorylation of Mig1 via the Reg1-Glc7 complex. Dephosphorylated Mig1
translocates to the nucleus and represses HXT2/4 transcription. Downregulation of
glucose transporter expression decreases glucose uptake. Limited availability of
intracellular glucose results in decreased G-6-P synthesis, which contributes, at least in
part, to G-6-P depletion.
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CHAPTER 5 FUTURE DIRECTIONS
The studies described here identified and characterized novel regulatory
mechanisms of inositol biosynthesis, both in yeast and mammalian cells. However,
many questions that arose from these studies await answers. The following discussion
describes questions that may be developed into research projects for future students.
1. How does Mck1 regulate MIPS activity in response to VPA?
In Chapter 2, I have shown that deletion of MCK1 decreased MIPS activity (Fig.
2-3). As discussed before, MIPS activity is regulated by phosphorylation (64).

In

addition, Mck1 has been shown to phosphorylate a protein substrate and therefore
regulate its activity (242). However, Mck1 did not phosphorylate MIPS in vitro (Fig. 2-5).
There are at least two possible explanations. First, the phosphorylation of MIPS by
Mck1 may require co-factors or scaffold proteins that target Mck1 to MIPS. The second
possibility is that Mck1 does not phosphorylate MIPS directly. Instead, Mck1 regulates a
down-stream pathway that phosphorylates MIPS. The mechanism whereby Mck1
regulates MIPS activity remains to be determined.
Mck1 has been shown to mediate VPA-caused MIPS inhibition (Fig. 2-4).
However, it is not clear how VPA regulates Mck1. In mammalian cells, Gsk3 activity is
regulated at the phosphorylation level by PI3K/Akt pathways (106,107). It is possible
that VPA regulates Mck1 by a conserved mechanism in yeast. Further investigation is
required to characterize the signaling pathway between VPA and Mck1.
In addition, the simultaneous deletion of MRK1, MDS1, and YGK3 results in
increased intracellular inositol levels, suggesting that at least one of these genes
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downregulates inositol synthesis. It will be interesting to study how these genes affect
inositol metabolism.
2. What is the role of inositol pyrophosphate in the regulation of inositol
synthesis in mammalian cells?
As discussed in Chapter 3, IP6K1-KO cells exhibited decreased DNA methylation
levels at the mIno1 promoter region (Figure 3-3). How does IP6K1 or its product, inositol
pyrophosphate, regulate DNA methylation? I hypothesize that inositol pyrophosphate
affects enzymatic activity of DNA methyltransferase. Future work should focus on
potential links between existing regulatory mechanisms of DNA methylation and
functions of inositol pyrophosphate.
I also showed that IP6K1 negatively regulates mIno1 expression (Fig. 3-2, 3-7).
IP6K1 has been reported to have direct interaction with chromatin (26), which suggests
a close association between IP6K1 and DNA. I hypothesize that IP6K1 or its product,
inositol pyrophosphate, represses mIno1 transcription by inhibiting the assembly of the
transcription complex. Addressing this hypothesis will benefit the characterization of
functions of inositol pyrophosphate in the regulation of inositol synthesis.
3. What is the role of VPA in regulating glucose metabolic flux?
Studies have been reported that VPA inhibits inositol synthesis and increases
glycolysis. G-6-P is the common substrate for both pathways. VPA also depletes
intracellular G-6-P levels, which is at the branch point of glycolysis, inositol synthesis,
the pentose phosphate pathway, and the glycogen synthesis pathway. These findings
suggest that many of the plethora of biochemical effects of VPA may result from
perturbation of G-6-P metabolism. It is of great importance to determine the effect of
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VPA on glucose metabolic flux. The elucidation of this question will greatly benefit the
understanding of the therapeutic mechanism of VPA.
Finally, I want to emphasize that we have certainly not finished the exciting
journey towards the exploration, identification, and characterization of functions of the
pivotal molecule inositol, and the underlying regulatory mechanisms that control its
synthesis. It is my privilege if my dissertation sparks new ideas for future students.
Together, we push science to a new frontier.
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ABSTRACT
NOVEL REGULATORY MECHANISMS OF INOSITOL BIOSYNTHESIS IN
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Myo-inositol is the precursor of all inositol containing molecules, including inositol
phosphates, phosphoinositides and glycosylphosphatidylinositols, which are signaling
molecules involved in many critical cellular functions. Perturbation of inositol metabolism
has been linked to neurological disorders. Although several widely-used anticonvulsants
and mood-stabilizing drugs have been shown to exert inositol depletion effects, the
mechanisms of action of the drugs and the role of inositol in these diseases are not
understood. Elucidation of the molecular control of inositol synthesis will shed light on
the pathologies of inositol related illnesses.
In Saccharomyces cerevisiae, deletion of the four glycogen synthase kinase-3
genes, MCK1, MRK1, MDS1, and YGK3, resulted in multiple features of inositol
depletion. My studies demonstrated that the MCK1 gene is required for normal inositol
homeostasis. mck1∆ and gsk3∆ (mck1∆mrk1∆mds1∆ygk3∆) cells exhibited similar
features of inositol depletion. MCK1 ablation led to decreased myo-inositol-3-phosphate

127

synthase (MIPS) activity and a decreased rate of inositol de novo synthesis. This is the
first demonstration that Mck1 controls inositol synthesis by regulating MIPS activity.
While elegant studies have revealed several inositol-regulating mechanisms in
yeast, very little is known about regulation of inositol synthesis in mammals. My studies
discovered that IP6K1, an inositol hexakisphosphate kinase that catalyzes the synthesis
of inositol pyrophosphate, negatively regulates inositol synthesis in mammalian cells.
Interestingly, IP6K1 preferentially bound to the phospholipid phosphatidic acid, and this
binding was required for IP6K1 nuclear localization and the transcriptional regulation of
Isyna1, which encodes mammalian MIPS. This is the first demonstration of the
molecular control of de novo synthesis of inositol in mammalian cells.
VPA depletes intracellular glucose 6-phosphate in yeast cells by an unidentified
mechanism. My studies discovered that VPA inhibits expression of hexose transporter
genes HXT2, HXT4, HXT6, and HXT7. Mig1, a DNA-binding transcription repressor that
translocates to the nucleus to repress gene expression under high glucose conditions,
is required to inhibit HXT2 and HXT4 expression. Interestingly, VPA triggered Mig1
nuclear localization under non-repressive conditions. Furthermore, ablation of REG1,
which regulates Mig1 translocation, reversed VPA-induced inhibition of HXT4
expression. These findings suggest that VPA may inhibit glucose uptake by activating
Mig1-mediated repression of hexose transporter genes.
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